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ABSTRACT OF DISSERTATION

DIVERGENCE IN NEURONAL CALCIUM DYSREGULATION IN BRAIN AGING
AND ANIMAL MODELS OF AD
Neuronal calcium dysregulation first garnered attention during the mid-1980’s as a
key factor in brain aging, which led to the formulation of the Ca2+ hypothesis of brain aging
and dementia. Indeed, many Ca2+-dependent cellular processes that change with age,
including an increase in the afterhyperpolarization, a decrease in long-term potentiation,
an increased susceptibility to long-term depression, and a reduction in short-term synaptic
plasticity, have been identified. It was later determined that increased intracellular Ca2+
with age was due to increased Ca2+ channel density, elevated release from intracellular
Ca2+ stores, and decreased Ca2+ buffering or clearance. Further, changes in intra- and
intercellular Ca2+-dependent processes can lead to poor learning and spatial mapping in
aged animals. As these are clear deficits in hippocampal function, many early studies
assumed Ca2+ dysregulation phenotypes in animal models of aging were similar to the
dysregulated cellular mechanisms seen in Alzheimer’s disease (AD) and other types of
dementia. However, with the development of transgenic models to recapitulate hallmark
AD phenotypes over the past 20 years, it has become apparent that the mishandling of Ca2+
is notably different across models.
Importantly, many of these results were obtained while measuring Ca2+ indirectly
and at limited ages. Thus, the once generalizable phenotypes associated with Ca2+
dysregulation, including increased intracellular Ca2+ and reduced synaptic communication,
appear to diverge in normal brain aging and AD. The following dissertation investigates
direct and indirect Ca2+ measures across the widely used 5xFAD familial AD mouse, as
well as the less common Aldh2-/- sporadic AD mouse model. Based on previous evidence,
it was hypothesized that a decrease in intracellular Ca2+ and associated processes would
manifest in both models across age. Key results showed a reduction in resting Ca2+ in the
5xFAD mice, while in the Aldh2-/- model only minor Ca2+-dependent processes showed a
genotype effect. These results highlight the non-generalizable nature of the Ca2+ hypothesis
of brain aging to AD phenotypes and emphasize the importance of genetic background
characterization, as well as underscore the complexity of cellular alterations in the
divergence of aging and neurodegeneration.
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CHAPTER 1. NEURONAL CALCIUM HANDLING IN AGING AND AD
1.1

The Calcium Hypothesis of Brain Aging and Dementia
In the mid-1980’s, a novel proposal revolutionized modern Alzheimer’s disease

(AD) research. This was the recognition of Ca2+ dysregulation as a variable involved in
brain aging and dementia which was subsequently coined the “Calcium Hypothesis of
Brain Aging and Dementia” [1-6]. In the initial proposal it was postulated that increased
neuronal intracellular Ca2+, with age, warrants excitotoxicity and subsequent cell death.
Since this early hypothesis, it has been shown that rather than an excitotoxicity phenotype,
neuronal hyperexcitability due to sustained intracellular Ca2+ levels and reduced clearance
are more accurate biomarkers of Ca2+ dysregulation. Some of this early work in rat and
rabbit animal models of brain aging showed aged neurons exhibiting enhanced influx of
Ca2+ through voltage-gated channels which led to both a larger Ca2+-dependent
afterhyperpolarization (AHP) and reduced short-term synaptic plasticity [2, 7-11]. Further,
alterations to mitochondrial and endoplasmic reticulum (ER) cytosolic Ca2+ buffering [1216], decreased release from intracellular stores [17], and reduced cytosolic clearance [1821] are recognized as important hallmarks of perturbed Ca2+ homeostasis in neurons.
Detection of these markers of dysregulated Ca2+ have led to advances in
understanding the complex regulatory mechanisms involved in neuronal network
communication, memory encoding, and cognition. Despite these encouraging insights,
there have been therapeutic limitations and misalignments of outcome measures between
normal brain aging and AD. Chapter 1 of this dissertation aims to address the current
status of Ca2+ homeostasis literature in normal brain aging and how it diverges during AD
progression. Chapters 2 and 4 are studies that measured Ca2+ in two different mouse
1

models of amyloidogenesis across age, while Chapter 3 highlights the differences
between the animals and the utility of using various models. Chapter 5 will conclude the
dissertation by summarizing and discussing results, addressing limitations of the studies,
and suggesting future directions.

1.2

Ca2+ Handling in Neuronal Physiology
Ca2+ is a versatile second-messenger signaling ion that has a fundamental role in

many cellular processes such as apoptosis, neurotransmitter release, mitochondrial
bioenergetics and free radical species formation, gene regulation, cell proliferation and
growth, membrane excitability, synaptic transmission, and plasticity [22-24]. Its functional
role in a neuron is carefully regulated, so much so that the concentration of intracellular
Ca2+ (50-200 nM) is 10,000 times less than in the extracellular space (1-2 mM) [25-28].
To maintain this sheer difference in concentration gradient, many protein complexes are
involved at the plasma membrane, cytosol, mitochondria, and ER [29].
At the plasma membrane, voltage-gated Ca2+ channels (VGCCs), ligand-gated Ca2+
channels (LGCCs) such as N-methyl-D-asparate (NMDA) and α-amino-3-hydroxy-5methylisoxazole-4- propionate (AMPA) receptors, and store-operated Ca2+ entry (SOCE)
channels regulate Ca2+ influx, while plasma membrane Ca2+ ATPase (PMCA) and Na+/
Ca2+ exchangers (NCX) are prominent regulators of Ca2+ efflux [24, 30-34]. NCX flux
Ca2+ into the extracellular space with low affinity, but high capacity during the recovery
phase of an action potential (AP) firing [35], while the PMCA has high affinity for Ca2+,
yet slow transportation in the extracellular matrix, positioning the PMCA channels to be
better equipped for maintaining resting state levels of Ca2+ [36, 37]. Within the intracellular
2

space, the ER’s ryanodine (RyR) and inositol (1, 4, 5)-trisphosphate (IP3) receptors and the
mitochondrial transport system play a critical role in maintaining intracellular Ca2+ store
homeostasis through release and clearance mechanisms [38-44]. It is through calciuminduced calcium release (CICR) and RyR/IP3R activation that cytosolic Ca2+ levels can rise
to 1-5 μM and trigger Ca2+-dependent signaling pathways. Intracellular Ca2+ stores in the
ER are then replenished via Ca2+ uptake through the sarco-endoplasmic reticulum Ca2+ATPase (SERCA) pumps. Further, through a mechanism called capacitive Ca2+ entry
(CCE) or store operated Ca2+ entry (SOCE), crosstalk between ORAI subunits at the
plasma membrane and STIM proteins at the ER aid in the regulation of ER Ca2+ levels [4547]. The following sections will describe in greater detail the cellular physiology of Ca2+
handling, alterations during aging, and changes to these processes in AD.

1.3

Membrane-bound Ca2+ Channels
1.3.1

NMDA Receptors

At the post-synapse are the hetero-tetrameric protein complex NMDA receptors. A
type of ligand-gated Ca2+ channel (LGCC), NMDARs are ionotropic glutamate receptors
that regulate the passing of Na+, K+, and Ca2+ ions into the intracellular space. Because
neurons have a negative resting membrane potential and the reversal potential of NMDARs
is ~0 mV, receptor activation is always an excitatory response. These excitatory responses
(i.e. excitatory postsynaptic potentials or EPSPs) grow in amplitude as the receptor is
activated, which influxes extracellular Ca2+ into the post-synaptic neuron. Importantly, the
inclusion of Ca2+ influx into the cytosolic space activates a signaling cascade of CICR.
Additionally, through nonspecific activation involving glutamate and glycine co-agonist
3

binding, as well as the depolarization of the plasma membrane to remove a Mg2+ that
occludes the NMDA channel, NMDARs facilitate long-term potentiation (LTP) and longterm depression (LTD) processes [48, 49]. It is through repetitive, synchronous stimulation
of the pre- and post-synapse at high and low frequencies that LTP and LTD are elicited,
respectively. These synaptic plasticity processes are believed to be largely associated with
memory encoding and erasure [50-54]. Moreover, Ca2+ influx via NMDA receptors at the
postsynaptic dendritic spines is necessary for LTP to be induced [55]. Conversely, when
NMDA receptors are either inhibited or quantitatively in deficit, depression of the synapse
may ensue [56]. With ties to memory and attention, it has been of interest to investigate
NMDA receptors and their function in brain aging research.
In aging, it has been shown that NMDA proteins and function are altered; however,
this has been relatively region specific, as such changes were noted in the hippocampus,
but not in cortical tissue. More specifically, reduced expression of NMDA protein localized
to region Cornu Ammonis-1 (CA1) has been observed in aged mice, rats, and rhesus
monkeys [57-67]. This observation is coupled with decreased NMDAR-mediated synaptic
response in aging, as electrophysiological studies have shown reduced EPSP amplitude by
50% [68, 69]. Various theories have been postulated to explain the overall reduction in
NMDAR density, such as decreased subunit expression, altered posttranslational
modification via kinase/phosphatase activity states, and decreases in local supporting cells
that are the source of essential amino acids [64, 67, 69-83]. However, due to inconsistencies
and contrasting outcomes in age-related loss of NMDARs, an explanation has remained
elusive. With the crucial role NMDARs have in synaptic communication, reductions in

4

NMDA proteins and function are expected in memory impairment and cognitive decline.
Thus, NMDA alterations are a robust marker of neuronal aging and deficits.
1.3.2

Voltage-gated Ca2+ Channels

Another source of neuronal Ca2+ influx from the extracellular space is through the
voltage-gated Ca2+ channels (VGCCs). These hetero-multimer protein channels are
embedded within the plasma membrane and are activated upon depolarization of the
membrane. Two classes of VGCCs have been identified: high-voltage-gated and lowvoltage-gated. As their names imply, high-voltage is dependent on a strong membrane
depolarization while low-voltage relies on a weak depolarization. High-voltage VGCCs
have been further classified as the L (Cav 1.1-3), P/Q (Cav 2.1), and N (Cav 2.2) type
channels, while low-voltage VGCCs are classified as either T (Cav 3.1) or R (Cav 2.3) type
based on their respective biophysical and pharmacological properties [84-94]. There has
been a wealth of evidence suggesting VGCCs are affected during brain aging as well. In
CA1 hippocampal neurons of aged rats, increased L-type voltage-gated calcium channel
(L-VGCC) density, Ca2+ currents, mRNA protein expression levels, and post-translational
phosphorylation state have been well characterized [80, 95-102]. That being said, the
application of Ca2+ channel blockers to reverse the effect of aging on L-VGCCs has
generated a lot of research interest.
Many previous studies have applied L-VGCC blockers such as nifedipine and
nimodipine to hippocampal slices to investigate Ca2+-mediated processes like the AHP and
long and short-term plasticity. Importantly, by inhibiting L-VGCC activity with blockers,
age-related deficits to synaptic strength and behavioral learning have been rescued [80,
103, 104]. Further, it has been observed that through blocking L-VGCCs, the amplitude of
5

the age-enhanced AHP is reduced and, notably, LTP induction is facilitated at lower
frequency stimulation while LTD induction is inhibited in aged animals [80, 105]. The
translatability of these findings is apparent too, as a multitude of studies have shown robust
improvements in hippocampal learning and memory through the blockade of L-VGCCs in
both aged animals and humans [8, 100, 106-119]. Surprisingly, L-VGCC alterations seem
to only be related to hippocampal-dependent memory, as expression patterns and function
of L-VGCCs in cortical neurons are not altered with age [120, 121]. Of interest, there is
also crosstalk between estrogen and L-VGCC expression, as they are negatively correlated;
L-VGCC density increases with age as estrogen decreases, perhaps underscoring a sex
difference that may be present in memory decline [122]. Thus, it comes with little surprise
that the use of L-VGCC blockers in studies of aging and cognitive impairment has been
widely explored. The clinical application of L-VGCCs is discussed in greater detail in
Chapter 1.8.

1.4

Intracellular Calcium Stores (ICS)
1.4.1

Endoplasmic Reticulum

CICR is a physiologic phenomenon to amplify the release of Ca2+ at the ER.
Through Ca2+ influx at the plasma membrane and activation of IP3Rs at the ER, Ca2+ is
released into the cytosol and further activates RyRs at the ER for even greater Ca2+ release.
Age-related decreases in IP3 receptor density have been reported in cerebellum and cortex.
Interestingly, however, these reductions do not seem to correlate with reduced IP3-induced
Ca2+ release [123-127]. Similarly, it should be noted that increased RyR responsiveness to
CICR has been observed in the presence of age-mediated increases in oxidative stress,
6

which incidentally has been suggested to increase IP3 receptor function, perhaps
highlighting the complexity of compensatory effects, especially when IP3 receptor function
is modified [128-132]. Further, in aged F344 rats, it has been shown that inhibiting the agedependent enhancement of CICR in hippocampal neurons reduces the AHP amplitude,
enhances LTP, inhibits LTD, and promotes NMDAR-mediated synaptic plasticity,
underscoring the widespread physiologic implications that dysregulated Ca2+ handling can
have on synaptic communication [133, 134]. Moreover, direct Ca2+ measures show
increased somatic Ca2+ and slow release (decreased rise time) from intracellular stores in
aged F344 rats [135]. These age-related differences are attenuated when the CICR
antagonist ryanodine is administered, further emphasizing the global effect that
dysregulated Ca2+ homeostasis has on a neuron.
1.4.2

Mitochondrial Ca2+ Handling

Mitochondria have a prominent role in maintenance of bioenergetics necessary for
cell survival and programmed death through the production of adenosine triphosphate
(ATP) and caspase activators/proteins needed for apoptosis [136, 137]. Of interest,
mitochondria also function as regulators of intracellular Ca2+ transients through uptake via
the mitochondrial Ca2+ uniporter (MCU), which in turn regulates mitochondrial
metabolism [38, 138-140]. Ca2+ is also transported back to the cytosol via the
mitochondrial NCX (mNCX) [141]. In aged cortical tissue of F344 rats, reduced
mitochondrial uptake of Ca2+ has been observed in comparison to younger aged animals
[142]. However, when elevated levels of Ca2+ enter the mitochondria, reactive oxygen
species (ROS) production increases, ATP synthesis is inhibited, and apoptosis is initiated,
highlighting a delicate threshold of mitochondrial Ca2+ regulation [143, 144]. In addition
7

to decreased Ca2+ uptake in aging, mitochondrial regulation of free oxygen radicals has
been observed to decline with age [145]; thus, it is perhaps unsurprising that the
relationship between Ca2+ dysregulation and ROS has garnered attention in brain aging and
dementia literature. Both Ca2+ dysregulation and ROS have been implicated in the genesis
of amyloid beta plaques and all three are believed promote one another. Chapter 1.10 goes
into greater detail on these phenotypes.
1.4.3

Cytosolic Ca2+ Transportation

To regulate the dynamic increases in cytosolic Ca2+ during depolarization and keep
intracellular concentrations of the cation low during resting state, neurons have robust Ca2+
signaling mechanisms to clear excess Ca2+ ions from the cytosolic space [146]. Ca2+
transport is achieved through the signaling of over 200 Ca2+ binding proteins (CBPs) that
are key modulators of Ca2+ signaling pathways [147]. CBPs can be subdivided into Ca2+
buffers (e.g. calbindin, parvalbumin, and calretinin) and Ca2+ sensors (e.g. calmodulin and
protein kinase C) [147, 148]. The CBPs help facilitate the flux of Ca2+ back into the ER
and mitochondria (sequestration), as well as the exchange of Ca2+ back into the
extracellular milieu (extrusion). The involvement of CBPs in aging has been unique to
CBP-type, as well as to tissue region specificity.
Many studies have examined different types of CBPs across age, yet findings have
been notably widespread. For example, decreased levels of CBPs such as calbindin and
calretinin have been observed in the hippocampus of aged rats [149, 150], while their levels
remained unchanged in the cerebellum [149]. Similarly, when calbindin immunoreactivity
was measured across age in rats and rabbits, significant decreases were detected in both the
dentate gyrus and subregion CA1 of the hippocampus in aged rats, but only in the dentate
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gyrus of aged rabbits [151]. In contrast to calbindin, interneurons containing parvalbumin
in the hippocampus had no changes in aged rats [150], but reduced levels of parvalbumin
in the medial septum-diagonal band that leads to the hippocampus have been noted [152].
Others have also suggested that a reduction in CBPs during aging may lead to decreased
function of the embedded proteins involved in sequestration and extrusion transport
systems, hence heightened intracellular Ca2+ levels [153-158]. Reductions of CBPs during
aging is not generalizable though, as the Ca2+ and Ca2+/calmodulin binding protein
phosphatase, calcineurin, has been demonstrated to play a direct role in increasing LVGCC function in aging [101, 159]. Further, it is important to note that decreased Ca2+
binding may be region or cell specific, as increased Ca2+ binding has been identified in
basal forebrain neurons during aging, perhaps suggesting the presence of an underlying
compensatory mechanism to regulate Ca2+ ion concentrations [16, 160, 161]. Irrespective
of irregular CBP results, there is clearly an important role that CBPs have in neuronal Ca2+
regulation that should continue to be explored.

1.5

Synaptic Plasticity
As highlighted in previous sections, age-dependent NMDAR loss and L-VGCC

functional increases (coupled with alterations to ICS signaling) impact both the excitability
and overall neural activity of hippocampal neurons. A classic measure of the association
between synaptic plasticity and memory is sustained synaptic strength using LTP outcome
measures [162]. A well-characterized phenotype of synaptic plasticity in aging is the
elevated activation threshold for LTP induction and reduced LTP duration [51, 52, 163],
perhaps meaning greater difficulty to encode memories. It is curious, however, that the
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larger AHP and enhanced Ca2+ levels during stimulation that are observed in aging do not
contribute to a lower activation threshold in LTP. Importantly though, the AHP is a postsynaptic potential, which likely explains the lack of effect it may impose on the synaptic
LTP activation threshold. Reduced LTD threshold, increased susceptibility to activating
LTD, and depotentiation (reduction in synaptic strength after it was initially potentiated)
have been illustrated as markers of poor synaptic plasticity in aging as well [18, 52, 164,
165]. Moreover, aging phenotypes of synaptic strength have not been exclusive to longterm synaptic plasticity. Another phenotype of impaired synaptic plasticity in aging has
been observed during repetitive synaptic stimulation (frequency facilitation), a form of
short-term synaptic plasticity, where failure to elicit growth of EPSPs is seen in aged F344
rats [10]. This finding has been coupled with the elevation of both postsynaptic intracellular
Ca2+ as well as L-VGCC activity in aged CA1 pyramidal neurons, a testament to the global
impact of dysregulated Ca2+ on network communication [11].

1.6

Afterhyperpolarization (AHP)
The communication between neurons is profoundly unique, incredibly complex,

and, importantly, well-regulated. In a sense, an AP can be thought of as the language used
to facilitate communication between neurons. Through repeated firing of APs, neurons
release neurotransmitters at their synapses to communicate with one another. It is through
specific patterns and frequencies that memories are encoded or forgotten. As a regulator of
repetitive AP firing, the post-burst afterhyperpolarization (AHP) is a neuronal mechanism
that prevents overexcitation [166] and its amplitude is dependent on the number and
frequency of APs during stimulation [167, 168]. In addition to the number and frequency
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of APs affecting AHP amplitude, the AHP of hippocampal pyramidal neurons has two subcomponents, medium and slow afterhyperpolarizations, that are Ca2+-dependent [169,
170]. The amplitude and duration of the AHP correlates with intracellular Ca2+
concentrations. Moreover, the AHP has been shown to be directly associated with learning,
as reductions in its amplitude have been previously described in rat and rabbit models
undergoing hippocampal-dependent tasks such as eyeblink conditioning [171-173],
context-fear conditioning [174], olfactory-discrimination [175, 176], and the Morris water
maze [177].
Conversely, when learning is impaired in aged animals, the post-burst AHP
amplitude is enhanced [171]. Though learning tasks ameliorate the amplitude of the Ca2+sensitive AHP, pharmacological treatments are effective in truncating the AHP magnitude
too. L-VGCC blockers nifedipine and nimodipine have been historically used to reduce
Ca2+ influx and decrease the AHP [80, 103, 104, 178-180], while 1,25VitD treatment on
cultured neurons has been proven effective as well [181]. Importantly, it has been widely
demonstrated that CA1 pyramidal neurons of aged animals have AHPs of significantly
greater amplitude compared to young counterparts [2, 9, 182]. This increase in AHP
amplitude of aged animals is due in part to higher concentrations of intracellular Ca2+ and
reflects perturbed Ca2+ regulatory mechanisms such as channel density at the plasma
membrane and clearance, buffering, and extrusion processes [133, 135, 165, 170, 183,
184]. Because the AHP relies so heavily on other Ca2+ regulating biophysical mechanisms,
it is considered a reliable indirect measure of neuronal Ca2+ handling.
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1.7

Sex Differences in Ca2+ and Ca2+-dependent Processes of Aged Neurons
Notably, sex hormones have been described to impact Ca2+ homeostasis as well,

and this is of considerable interest in aging research, as sex is considered a predisposing
feature of AD development [185]. For example, treatment with estrogen has been shown
to increase NMDA receptor density in aged animals [186], as well as elevate dendritic
spines of CA1 neurons in young rats [187], but alterations were only present in those
specific age groups. However, estrogen treatments in ovariectomized primates elicit greater
hippocampal spines and performance of hippocampus-dependent cognitive tasks in both
young and aged animals, highlighting a clear role estrogen plays in learning and memory
[188, 189]. Why there is a disconnect between estrogen effects across species remains to
be determined. As estrogen has demonstrated an effect on learning and memory, its use in
synaptic plasticity is of interest as well.
Through whole cell electrophysiological recordings, application of 17betaestradiol (a potent estrogen) to medial vestibular nucleus neurons of rat brainstem slices
induces synaptic LTP and inhibits LTD induction, while dihydrotestosterone induces
synaptic LTD, which was corroborated by an abundance of estrogen and androgen
receptors in MVN neurons [190]. Further, high doses of 17beta-estradiol have been shown
to inhibit intracellular Ca2+ release in gerbil CA1 pyramidal neurons [191]. This work has
been corroborated through the identification of an enhanced AHP in aged ovariectomized
F344 rats and the reduction in amplitude upon direct application of 17beta-estradiol
benzoate to hippocampal slices [102], as well as an estradiol-mediated increase in the slow
afterdepolarization amplitude of mice [192]. Interestingly, 17beta-estradiol benzoate bath
occludes the attenuation of the AHP with the L-channel blocker nifedipine, suggesting
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estrogen derivatives modulate the AHP through a different mechanism other than L-VGCC
blockade. Through and through, it is evident that the crosstalk between estrogen and Ca2+
is essential to neuronal homeostasis and supports the importance of including sex
difference investigation in studies of aging.

1.8

Ca2+ and Cognition
Arguably the most forthright phenotype of brain aging, cognitive decline has been

long thought to be the result of neuronal loss with age in contemporary culture. However,
many studies have illustrated a non-significant reduction in neurons across human,
monkey, and rodent models, questioning the validity of this theory [193-198]. Rather,
decline in cognition has been suggested to depend on synaptic alterations and
neurotransmission limitations [199]. These changes with age, however, are more-subtle
than reductions in synaptic density and have been mostly absent in hippocampal tissue
during aging [199, 200]. Instead, alterations in synaptic communication during aging have
manifested in Ca2+-dependent processes like a reduced excitatory postsynaptic potential
[10, 18, 201] and an increased AHP current (reduces neuronal excitability), as previously
noted in Chapters 1.1 and 1.3.1 [165, 202]. Thus, it has been of interest in clinical trials to
test the effect of Ca2+ blockers on cognitive deficits in aging human populations, especially
AD.
As the purpose of basic research is the hopeful translatability for clinical use in
humans, the identification of perturbed neuronal Ca2+ handling in AD led to the exploration
of Ca2+ channel blockers as a form of treatment. Nimodipine has been a commonly used
drug in clinical trials due to its ability to readily traverse the blood-brain barrier, yet these
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results have been controversial. Indeed, improved memory and attention from nimodipine
treatment was observed in patients of age-related dementia in early trials [117, 203, 204].
However, because nimodipine is an antihypertensive drug used in the prevention of
subarachnoid hemorrhaging as a vasodilator, it has been speculated that its effectiveness in
AD pertains specifically to treating vascular-related symptoms of vascular dementia [205,
206]. Moreover, meta-analyses suggest VGCCs have a limited role in vascular dementia
progression [205]. Nevertheless, the use of other Ca2+ channel blockers in the treatment of
dementia prevention have also been tested, but yielded similarly inconsistent results.
Antihypertensive Ca2+ channel blockers like nitrendipine and nilvadipine have been shown
to temporarily reduce mild cognitive impairment progression, while nifedipine, diltiazem,
verapamil, and amlodipine were found to be ineffective [207-209]. Thus, while Ca2+
channel blockers may play a potential role in treating AD, they clearly are not enough to
effectively address the multi-faceted cellular alterations that drive disease progression.

1.9

Alzheimer’s Disease
AD is a devastating neurodegenerative disease state first described by Alois

Alzheimer in 1906, that is characterized by beta amyloid (Aβ) deposits,
hyperphosphorylated tau protein tangles, dysregulated Ca2+ homeostasis, elevated
oxidative stress, and altered neuroinflammatory markers. The global impact of each of
these hallmarks can promote impaired cognitive function, memory deficits, and behavioral
problems, leading to reduced quality of living and need for assisted care. To elucidate the
underlying mechanisms that drive AD progression, multiple hypotheses have been
proposed to pinpoint an initiating marker that propagates other pervasive cellular
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alterations and, ultimately, poor cognition and behavior. However, though there is
substantial evidence suggesting that amyloid, tau, dysregulated Ca2+, inflammation,
oxidative stress, and even metal ion dysregulation each participate in the pathogenesis of
AD, no singular biomarker accounts for the extensive cascade of detrimental cellular events
that promote AD [210, 211].
Despite the lack of a single AD hypothesis to explain phenotype progression, this
should not detract from the importance of the data that has been collected within each
respective hypothesis’ field of research. The paucity of identifying an AD treatment that
addresses each hallmark speaks to the complexity of the disease and likely suggests
multiple initiating events are intertwined and occur much earlier than the manifestation of
amyloid and tau, synaptic loss, and cognitive decline. Thus, the interplay of early AD
phenotypes such as Ca2+ dysregulation and oxidative stress may be important to further
investigate. Because normal brain aging is devoid of amyloid plaque deposits and
phosphorylated tau and there is a prevalence of altered Ca2+ handling in both aging proper
and AD, an assumption that AD may be an advanced form of aging has been suggested.
However, a growing body of evidence detailing a misalignment of outcome measures
between aging and AD suggests a potential divergence at the neuronal level. Further, these
misaligned phenotypes may even suggest that the Calcium Hypothesis of Brain Aging and
Dementia is not as generalizable as previously thought. The following sections highlight
deviations in Ca2+-dependent processes in AD models of aging and segue into two studies
that investigate Ca2+ outcome measures across age in mouse models of AD.
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1.10 Aβ and Ca2+ in Culture and Animal Models of AD
The amyloid precursor protein (APP) is a type I membrane protein that is
proteolytically processed to generate toxic Aβ species in AD [212]. Though APP is
expressed in many tissue types, its expression and improper splicing in AD gives rise to
insoluble extracellular Aβ monomers and oligomers in the brain. It is through the
processing via β and γ secretases and aggregation of insoluble Aβ peptides that amyloid
deposits accumulate in the AD brain, which led to the synthesis of the amyloid hypothesis
[213-217]. Early evidence has suggested Aβ as an influencing factor in dysregulated Ca2+
homeostasis in AD, such that Aβ oligomers may create Ca2+-permeable channels in the cell
membrane [218, 219]. In initial cell culture studies, the addition of Aβ to cultured neurons
was shown to elevate intracellular Ca2+ concentrations [220, 221]. Further, Aβ has also
been shown to elicit ROS production and subsequent membrane lipid peroxidation, leading
to impairments of Ca2+ transporters at the plasma membrane and elevating intracellular
Ca2+ concentrations [222, 223]. With clear detrimental impact to neuronal health, studies
have also measured the influence Aβ has on cell-to-cell neuronal communication such as
synaptic plasticity.
Reduced synaptic strength and synaptic loss are key markers of AD progression.
As such, studies have investigated the impact of Aβ oligomers on synaptic plasticity. Not
only have decreased surface NMDA receptors in APP mutated transgenic models [224]
been identified, but an inhibition of LTP induction in both in vivo and in vitro models has
been observed as well, although this was not present with LTD [225-228]. The latter result
is especially surprising, considering both mechanisms are widely thought to be involved in
memory encoding and erasure. Interestingly, Aβ oligomers have also been shown to induce
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the production of ROS through NMDAR-dependent activation in hippocampal cultures
[229]. In pyramidal neurons of Sprague-Dawley rats, Aβ reduces dendritic spine density,
impairs electrophysiologically active synapses [230], and facilitates NMDA-mediated
excitotoxicity [229, 231], which may underscore why such pronounced synaptic deficits
are present in AD. It is important to note, however, that while Aβ increases intracellular
Ca2+, elevated intracellular Ca2+ can also promote Aβ production, which suggests a cyclic
relationship between the two events and further complicates detection of the initiating
factor(s) that begin the AD cascade [232-235].

1.11 Plasma Membrane Ca2+ Handling in AD Models
1.11.1 Ca2+ Influx Via VGCCs at the Plasma Membrane in AD Models
In an attempt to gain a greater understanding of Aβ’s effect on Ca2+-mediated
processes at the plasma membrane such as Ca2+ influx via VGCCs, studies have looked at
VGCC density and function in culture and animal models of amyloidogenesis. Growing
evidence has shown Aβ impacts neuronal health through increased L-type VGCC influx of
current, increased intracellular Ca2+, and impaired synaptic plasticity [236]. In studies of
cultured rat neurons, Aβ treatment increases free radical production and subsequently
elevates Ca2+ influx through L- and N-VGCCs [237], while also elevating N- and P-type
VGCC current amplitude [238]. Similarly, L-type Cav1.2 and 1.3 subunit surface proteins
and channel activity have been observed to increase in the presence of acute Aβ oligomer
exposure in culture [239, 240], although chronic exposure evoked decreased L-type Cav1.2
surface proteins [239]. Though many cell culture studies have provided evidence of a
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negative impact of Aβ on VGCCs, it has been of interest to investigate VGCCs in AD
animal models to uncover physiologic alterations in the progression of AD.
A limited number of studies have investigated L-VGCCs in models of AD with the
inclusion of aging. Of these, an age-dependent increase in L-VGCC density specific to
CA1 neurons of 3xTg mice has been observed, but not in neurons of subfield CA3 or the
dentate gyrus [241]. Strangely, in a similar study conducted by our group using a double
knock-in mouse model and the same patch-clamp electrophysiological technique,
reductions in L-VGCC channel activity was observed in mice of the same age (12-14 mo.)
[242]. Further, a reduction in Cav1.2 protein expression has been seen in 2xTg mice of 9
months compared to WT littermates using a similar biochemical approach [243]. Perhaps
such drastic differences in phenotypes between the similar mouse models can be attributed
to the inclusion of the MAPT (tau) gene mutation in the 3xTg design, although many other
factors may be influencing the generation of the phenotype as well. Nevertheless, these
deviations from the early findings of increased L-VGCC density and activity in aged F344
rats by Thibault and Landfield highlight a clear misalignment between normal brain aging
and brain aging in AD [97]. Considering the growing body of literature linking L-VGCC
alterations to cognitive and spatial memory deficits [244, 245] and the controversial
evidence of L-VGCC blocker effectiveness in clinical trials [246-250], it is of interest to
continue efforts to elucidate the role of these channels in AD progression.
1.11.2 Synaptic Dysfunction and Tau in AD Models
Studies exposing NMDAR to concentrations of Aβ in vitro, ex vivo, and in vivo
have illustrated a direct negative impact on synaptic connectivity. Some of the markers of
synaptic dysfunction include the reduction of activity to the NMDA subunit GluN2A and
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downregulation of synaptic proteins PSD-95 and synaptophysin [251], subunit GluN2Bmediated LTP impairment [252], and even rescuing learning and memory through the
enhancement of GluN2B NMDAR surface trafficking [253]. There have also been studies
linking synaptic dysfunction in AD to the hyperphosphorylation of tau, which adds to the
complexity of cellular changes as they transpire. As tau protein is normally localized to
neuronal axons, it is indeed problematic that in the AD brain, tau is aberrantly translocated
to the somatodendritic region of cells [254, 255]. Of particular interest, recent evidence has
suggested that this mislocalization of tau protein and subsequent hyperphosphorylation
may be due, in part, to overexcitation of NMDA and AMPA receptors resulting from
excess glutamate stimulation [256], which aligns with epilepsy phenotypes that have been
observed in AD [257-260]. However, as tau mislocalization to dendritic spines has been
implicated in the degeneration of synaptic activity [261], it is clear that a better
establishment of a time orientation between the manifestation of synaptic dysfunction and
somatodendritic tau accumulation is necessary to more carefully link the coupled
phenotypes [262].
1.11.3 Ca2+ Efflux at the Plasma Membrane in AD Models
Given the direct impact that Aβ has on NMDA receptors [224], it is unsurprising
that Aβ oligomers impact NCX and PMCA as well. Existing as three different isoforms
with varying tissue-specific expression patterns [263], increased NCX activity has been
observed in post-mortem cerebral brain tissue of AD patients [264]. This very well may be
a compensatory mechanism to reduce increased levels of cytosolic Ca2+ caused by Aβ load.
When co-localized with Aβ, NCX isoforms are increased in synaptosomes [265], and
overproduction of Aβ promotes calpain-mediated cleavage of isoform NCX3, a regulator
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protein of Ca2+ current during synaptic activation [266, 267]. Despite this, contradictory
findings have revealed a downregulation of protein and mRNA levels of NCX2 and NCX3
isoforms in hippocampal CA1 neurons of APP transgenic mice [268]. It is unclear whether
there is a brain region-specific difference in NCX expression or if Aβ oligomers affect this
Ca2+ transporter differently across human and rodent tissue preparations. Treatment with
Aβ oligomers, tau, and H2O2 have been shown to inhibit the functional activity of PMCAs
as well [269, 270].

1.12 ICS in AD Models
1.12.1 Endoplasmic Reticulum and Presenilin Mutations
In addition to the substrate APP, ER presenilin (PS) mutations are commonly
incorporated into the genetic makeup of mouse models of familial AD [271]. The inclusion
of the PS mutation in these models has been crucial to the progression of Ca2+
dyshomeostasis research in AD since a link between PS and Ca2+ was first identified in
fibroblasts of patients with familial AD (fAD) [272, 273]. This discovery launched many
subsequent studies showing PS mutations are linked to increased Ca2+ release through
‘leaky channels’ of the ER in human fibroblast samples, cell culture, and animal models
[127, 272, 274-281]. Resting cytosolic Ca2+ is elevated in the 3xTg and APP(SWE)
transgenic models compared to WT controls; however, this difference is partially
attenuated with the application of either an IP3R blocker or VGCC blocker, but not with a
RyR antagonist [282]. One hypothesis to explain increased ER Ca2+ release has been that
ER Ca2+ stores are simply overloaded, hence greater expulsion [277, 283, 284].
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Despite findings showing enhanced ER Ca2+ stores, many studies have also
observed either no changes or even reductions in ER Ca2+ [285-288]. Nevertheless,
previous studies investigating neuronal Ca2+ either directly or indirectly in transgenic AD
models have often reported increased resting or stimulated cytosolic Ca2+ levels compared
to WT littermates [281, 289-300]. This, perhaps, implicates PS mutations as participating
in perturbed cytosolic Ca2+ levels. However, with so many inconsistent outcome measures
and the lack of PS mutations in the more common form of AD, sporadic AD (sAD), PSdependent Ca2+ measures cannot be generalized to all AD models. Further, it is important
to note that most direct measures of Ca2+ in these models were acquired at single timepoints, which precludes observing associations between Ca2+ and aging. Thus, there is a
complication as to whether increased intracellular Ca2+ is merely the product of failed ER
Ca2+ channels, aging, or both.
1.12.2 Endoplasmic Reticulum and IP3R
In an attempt to better understand ER Ca2+ release in models of AD, it has been of
interest to look at IP3R changes as well. Compared to reductions of IP3R primarily observed
in cerebellar and cortical rodent samples, it has been shown that in autopsied human AD
patients, IP3R density is significantly reduced in both hippocampus and parietal lobe tissue,
while no significant decreases are present in the frontal, occipital, or temporal lobes [301].
Interestingly, in a transgenic model that overexpresses the IP3 receptor regulatory protein
IP3K-A three-fold in excitatory hippocampal neurons, presynaptic release probability of
evoked responses and miniature excitatory postsynaptic current amplitudes were increased
and LTD was inhibited, while novel object recognition and radial arm maze tasks were
partially impaired, indicating overcorrections are not always beneficial [302]. This is
21

surprising, considering previous evidence has indicated IP3K-A is highly involved in
synaptic plasticity, as it accumulates in dendritic spines and has critical dual roles in
developing and mature synapses [127, 303]. That being said, an increase in resting Ca2+ of
pyramidal cortical neuron spines and dendrites has been reported in AD transgenic animals
[282, 304], suggesting deficits in IP3R may be contributing to synaptic impairments in AD.
More evidence is needed to better define the relationship between IP3R and synaptic loss
in AD.
1.12.3 CBPs in AD Models
Similar to what has been observed in aging, decreases in calbindin gene expression
have been seen in both hippocampus and nucleus basalis of AD human brain samples,
suggesting a failed Ca2+ buffering mechanism may contribute to dysregulated Ca2+ levels
as well [305]. Conversely, when either calbindin or calsenilin CBPs are overexpressed in
culture, Aβ-induced intracellular Ca2+ level elevations are significantly reduced [306-308].
Perhaps reminiscent of early CBP studies, calbindin and parvalbumin proteins in the
hippocampus of young (3 mo.) knock-in APPswe/PS1dE9 mice have increased
immunoreactivity compared to WT counterparts, suggesting an underlying mechanism to
regulate Ca2+ and synaptic plasticity in early disease-state [309]. Comparatively, by 12
months of age, calbindin immunoreactivity is significantly reduced, illustrating a threshold
for compensation being met and failing, which could contribute to the increased resting
Ca2+ phenotype commonly observed in APP/PS1 transgenic models. Importantly, in a
novel study comparing the classic 5xFAD AD mouse model to a calbindin KO 5xFAD
crossbreed (CBKO.5XFAD), the calbindin KO model has significantly greater neuronal
loss, reduced NMDA receptor density, and decreased synaptophysin in the subiculum,
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further highlighting the need for a robust Ca2+ buffering system in maintenance of synaptic
strength [310]. Failure of neuronal Ca2+ buffering in AD likely enhances widespread
impact to overall cell health and network communication.
1.12.4 Mitochondrial Changes in AD
Considering the dire nature of regulated mitochondrial function in providing
optimal bioenergetics for cell health, it comes with little surprise that impaired
mitochondrial function in AD results in a cascade of cellular deficiencies and even cell
death. With mitochondrial impairment during the progression of AD, the generation of
ROS becomes less regulated, and damage to lipid membranes of both internal organelles
and the plasma membrane ensues [311]. In fact, in a delicate study examining APP
transgenic mice gene profiles before, during, and after the development of amyloid plaque
deposits, a compensatory upregulation of mitochondria-specific genes was detected as
amyloid plaque deposits progressed [312]. Surely, this can be interpreted as an internal
defense mechanism in order to preserve mitochondrial integrity. However, in a disease
state like AD, the magnitude of Aβ and tau-induced cellular impairments is likely too great
for compensatory mechanisms to override in an attempt to maintain cell integrity.
In models of overexpressed tau protein, decreases in mitochondrial complex I (the
largest and most complex enzyme of the electron transport chain), ATP, morphology,
fusion/fission proteins, and oxidative stress protection have been noted [313, 314], while
increases in free oxygen radicals, synaptic deficits, and cognitive decline are propagated
[314, 315]. In fact, point-mutations to induce phosphorylation on various sites of tau has
been shown to be impactful to the gravity of mitochondrial damage, further highlighting
the extent of biological variability in animal models that genetic mutations influence [315].
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Additionally, because AD is a complicated disease saturated with etiologies of both Aβ
and tau tangles, in a study looking at AD-related protein mutations in aged 3xTg transgenic
mice, 24 APP and tau-dependent mutations were detected and 1/3 were linked to
dysregulated complexes of the oxidative phosphorylation system, synthesis of ATP, and
regulation of ROS [316]. Thus, changes in mitochondrial Ca2+, though seemingly minor,
can have a devastating impact on many downstream signaling pathways.

1.13 Synaptic Plasticity and Oxidative Stress in Models of AD
As neuronal connectivity and synaptic plasticity impairments are closely linked to
cognitive decline, modeling physiologic changes of synaptic deficits in the context of AD
pathologies demonstrates the fragility of regulatory cellular mechanisms. Many studies
have demonstrated a profound correlation between elevated Aβ and memory impairment
[317-320]. However, while decline in synaptic connectivity, rather than neuronal loss, has
been suggested to more closely bode cognitive reduction in AD [321], it is interesting to
note that in several AD models with overexpressed APP, impaired LTP precedes synaptic
loss and neuronal death [322-324]. Moreover, in triple transgenic mice with both tau and
amyloid mutations, drastic synaptic deficits (including reduced LTP) have been observed
in an age-dependent manner prior to tau and amyloid manifestation [325]. Of interest, while
similar results are observed in a double transgenic model of APP and PS1 overexpression,
short-term memory is impaired first, followed by long-term months later as amyloid burden
worsened [326]. However, in a unique model of only tauopathy (devoid of amyloid or APP
mutations), severe impairment in LTP maintenance are observed with aging, which
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underscores how tau-like pathologies alone are enough to drastically inhibit synaptic
plasticity in AD [327].
While the impact of amyloid and tau on synaptic plasticity is certainly a relevant
association to be studied in AD, the link between mitochondrial damage/oxidative stress
and synaptic loss is of importance too, as increased ROS is a common hallmark of the AD
brain. Strangely, the results of observing the relationship between oxidative stress and
synaptic plasticity have been unexpected. Studies have shown that in young transgenic
mice with overexpressed intracellular and extracellular superoxide dismutase 1 (SOD-1),
an enzyme that reduces oxidative stress, an LTP impairment and memory deficit is
observed [328-330]. However, in older mice these phenotypic impairments were not only
rescued, but actually improved compared to older WT counterparts and young transgenic
mice [331, 332]. Similarly, in a transgenic model of Aβ-induced LTP impairment, both the
overexpression of mitochondrial SOD-2 and administration of antioxidant ROS scavenger
MitoQ are able to rescue synaptic deficits [319, 333]. Together, this evidence supports
previous work suggesting physiologic concentrations of ROS are necessary in synaptic
events (such as LTP induction) in both adolescence and aging [334]. It has become a
paradox, however, as aging studies have found hydrogen peroxide inhibits LTP in both
young and aged animals [331].
Given the growing body of evidence that Aβ proximity to neurons increases
neuronal hyperexcitability [335-340] and impairs glutamatergic neurotransmission [341343], perhaps increased resting Ca2+ in AD is to be expected. It is important to note that in
addition to studies illustrating an increase in neuronal hyperexcitability when in close
proximity to Aβ plaques, others have also shown that soluble Aβ will not only reduce
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glutamate reuptake, but promote LTD [344]. Reduction of glutamate reuptake and excess
glutamate remaining in the synaptic cleft, aligns well with the promotion of
hyperexcitability. Bezprozvanny and colleagues have even posited changes in ER Ca2+
stores and handling may be a compensatory mechanism to counterbalance increased
neuronal hyperexcitability and impaired neuronal network activity previously observed in
AD mouse models [257, 304, 335, 345-347]. Given synaptic impairment and loss are so
devastating to functional cognition, maintaining neuronal health integrity during
deleterious conditions caused by Aβ is likely a high priority of many organelles.

1.14 Afterhyperpolarization in AD
As the post-synaptic AHP has historically been shown to be enhanced with aging,
it has been of interest to measure this Ca2+-dependent phenotype in the context of AD as
well, especially considering the observation of elevated Ca2+ in response to Aβ load. The
evidence implicating an enhanced AHP alongside increased cytosolic Ca2+ in models of
AD have been inconsistent, however, as measuring patch clamp recordings of Wistar rat
cortical tissue sections exposed to low and high concentrations of Aβ has provided
counterintuitive results [347]. Low concentrations of Aβ elevates the amplitude of the AHP
as well as expectedly reduces neuronal excitability. Surprisingly, however, the
administration of high Aβ concentration reduced the AHP amplitude of these neurons and
increased their excitability. Importantly, as the authors speculate, Aβ could be acting on
ion channels in both a time- and concentration-dependent manner, such that internalization
or expression patterns of channels on the plasma membrane are affected. Given AD is a
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disease of progressive worsening phenotypes, the inclusion of aging in a physiologic
system may offer a broader scope of characterizing the AHP in AD.
Indeed, measures of the AHP over a time course in animal models of AD offers a
physiologically relevant modality that single-timepoint studies lack. Similarly, an elevated
AHP and reduced neuronal excitability have been characterized in the 5xFAD mouse by 8
months of age compared to WT littermates using the whole-cell patch clamp technique
[294]. However, measuring the AHP in non-Tg, PS1KI, 3xTg, and APPSweTauP301L
models at 1.5, 6, and 18 months using the same approach has shown an increased AHP by
18 months and only within each respective model, not across genotype [127]. Interestingly,
in a recent study by our group looking at the AHP in young (2 mo.) genetically modified
5xFAD mice with slower-developing phenotypes and using the sharp electrode technique,
a reduction in the AHP amplitude was observed in comparison to WT littermates [348].
Unfortunately, due to a limited number of studies measuring the AHP across aging in
models of amyloidogenesis, variance in the genetic makeup, and use of different
electrophysiological techniques, more data is needed to sufficiently address the lack of
consistencies in prior work.

1.15 Estrogen and Ca2+ in AD
Women are more than 1.5-3 times as likely as men to develop Alzheimer’s disease
[185]. This could be due to the large shift in endogenous hormones that women experience
during post-menopause, which downregulates the neuroprotective effect of sex steroids in
the brain and their involvement in Aβ accumulation [349-352]. Of interest, estrogen
replacement therapy has been shown not only to reduce the incidence of AD in post27

menopausal women [96, 353-357], but also improve cognition in women AD patients as
well [358-361]. Thus, the inclusion of sex and estrogen therapies in neuronal Ca2+ research
is an important consideration that should not be overlooked.
As estrogen therapies have been long thought to possess neuroprotective properties,
the accumulating evidence of their effect on Ca2+ therapies comes with little surprise. A
recent study examined the magnitude of injury that cultured PC12 cells exposed to Aβ
endure when treated with the genistein, a phytoestrogen compound. Down-regulation of
CaM-CaMKIV signaling pathway protein expression is observed in the genistein treated
cells, as well as improved cell rate survival and decreased cell damage [362]. Similarly,
genistein has also been shown to prevent Aβ-mediated reductions in Ca2+-dependent
protein complexes like PKC pathway activity for neuronal plasticity, generation of ROS,
synaptic markers synaptophysin and PSD-95, and NMDAR subunits NR1 and NR2B [363365]. These findings are not exclusive to one estrogen derivative, however, as the use
alpha-ZAL phytoestrogen not only ameliorates Aβ-induced apoptosis, but also prevents
the increase of calpain2, a marker indicative of intracellular Ca2+ overload [366].
Additionally, the estrogen receptor agonist hesperetin protects against hydrogen peroxide
induced oxidative stress and the subsequent rise in cytosolic Ca2+ and caspase-3 activity
[367]. Beta-estradiol can also mitigate C31-, an APP derivative, mediated increases in
VGCC current activity as well [368]. Though the clear link between estrogen and Ca2+
processes is robust, the inclusion of an aging component in rodent models would bolster
the understanding of their relationship in the progression of AD.
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1.16 Divergence between Normal Aging and AD
Undoubtedly, the last 40 years of investigating the role of Ca2+ in AD research has
been invaluable to understanding the underlying mechanisms of the disease state. As Ca2+
is an essential secondary messenger in neuronal function, it comes without surprise that an
innumerable amount of evidence has illustrated a role of Ca2+ in both normal brain aging
and in the pathogenic AD brain. Indeed, altered Ca2+ signaling and levels are present in
both states. However, a misalignment of outcome measures, as well as inconsistent
findings, warrant the question of whether Ca2+ dysregulation is the byproduct of aging or
a precipitating factor that promotes AD progression.
As aging is the top risk factor for AD development [369-375], perhaps the
misalignment of Ca2+ dysregulation phenotypes in normal brain aging and AD suggest
perturbed Ca2+ homeostasis results from a common mechanism that, when altered, diverges
normal brain aging and AD. The presence of intra- and extracellular alterations like
hyperphosphorylated tau and Aβ in AD may exacerbate Ca2+-dependent alterations through
bi-directional interplay, hence the capacity of phenotypes such as Aβ and Ca2+
dysregulation to cyclically promote one another. Without the presence of Aβ deposits
ubiquitously targeting Ca2+ channels, signaling elements, and synaptic plasticity proteins
in the normal aged brain, it could be that Ca2+ dysregulation is a more linear process that
aligns better with aging. However, because AD phenotypes are obviously not present in
normal brain aging, it is challenging to accurately characterize the presence and
relationship of Ca2+ dysregulation in aging proper and AD.
Unfortunately, there have been a limited number of studies that have carefully
measured neuronal Ca2+ handling progression in alignment with aging. Many of the early
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studies investigating the relationship between Ca2+ and Aβ were conducted in culture,
which may have hindered the consideration of aging on physiological variables. In in vivo
work (where in-tact physiologic connections are considered), these animal models often
have aggressive phenotypes at young ages and subtle underlying phenotypes like neuronal
Ca2+ handling are veiled by more severe cellular alterations. Clearly there is a relationship
between the regulation of Ca2+ and Aβ, yet culture preparations do not reflect the impact
of synaptic deficits on cognitive impairment that is demonstrated in in vivo models of
aging. Considering synaptic loss and reductions in LTP have been observed prior to Aβ
and tau burden, along with the essential role Ca2+ plays in synaptic plasticity, it appears
that initial and progressive neuronal Ca2+ changes require greater attention.
With respect to a paucity of studies exploring neuronal Ca2+ handling ex vivo across
age, the following two studies aimed to accomplish 1) measuring direct and indirect Ca2+
before, during, and after amyloidogenesis timepoints, 2) comparing these outcome
measures between models of fAD and sAD, and 3) aligning these results with previous
evidence of Ca2+ dysregulation in normal brain aging and transgenic AD animal models.
Because fAD only represents a fraction of total AD cases, the first study looked at Ca2+
and Ca2+-dependent processes in an alternative sporadic model of AD that generates
unregulated quantities of lipid peroxidation byproduct HNE at a young age to elicit ADlike phenotypes. The second study focused on acquiring the same direct and indirect
measures of Ca2+ in a genetically altered 5xFAD mouse model that generates AD
phenotypes more slowly to better align with aging. Additionally, sex differences were
assessed in the latter study. With the inclusion of distinct age time-points in the acquisition
of electrophysiological and direct Ca2+ imaging measures, a linear relationship between
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Ca2+ dysregulation, oxidative stress, Aβ, and cognitive impairment could be derived. It was
hypothesized that Ca2+ dysregulation would be present in each model before the
development of Aβ deposit or oxidative stress phenotypes, and progressively worsen with
age as Aβ load and ROS increased.
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The following manuscript was published in the Journal of Alzheimer’s Disease: J
Alzheimers Dis. 2020 Sep 5. pii: JAD200617. doi: 10.3233/JAD-200617. Aldh2-/- mouse
colonies were maintained at Queen’s University via the lab of B.M. Bennett and shipped
to the University of Kentucky in several cohorts. All electrophysiological recordings and
Ca2+ imaging experiments were performed by A.O. Ghoweri through the guidance of O.
Thibault and J.C. Gant. LTP electrophysiological recordings and analyses were conducted
by P. Gagolewicz under the guidance of R.D. Andrew and B.M. Bennett. Manuscript
writing and editing was established by A.O. Ghoweri, O. Thibault, H.N. Frazier, and B.M.
Bennett. The purpose of the following study was to identify a relationship between Ca2+
dysregulation and oxidative stress in a mouse model of increased free oxygen radical
burden through the knock down of the ALDH2 gene. In this model of sporadic Alzheimer’s
disease, early-life elevated levels of oxidative stress lead to severe synaptic deficits, the
presence of amyloid deposits, and cognitive decline in a progressive age-dependent manner
[376-378]. Oxidative stress is a neuronal marker with the capacity to elicit Ca2+
dysregulation, and vice versa, however, while both are present in AD, their relationship
during the initiating stage of disease development is poorly understood. As homeostatic
Ca2+ is necessary for important neuronal processes like action potential signaling and
synaptic plasticity, it was of interest to measure Ca2+ handling across age in the context of
heightened oxidative stress via ALDH2 knockout. We hope that the novelty of this sporadic
AD mouse model helps to broaden the understanding of disease progression beyond the
scope of APP and PSEN1 gene mutations that are commonly featured in familial AD
models.
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2.1

Abstract
Dysregulated signaling in neurons and astrocytes participates in pathophysiological

alterations seen in the Alzheimer’s disease brain, including increases in amyloid-β,
hyperphosphorylated tau, inflammation, Ca2+ dysregulation, and oxidative stress. These
are often noted prior to the development of behavioral, cognitive, and non-cognitive
deficits. However, the extent to which these pathological changes function together or
independently is unclear. Little is known about the temporal relationship between Ca2+
dysregulation and oxidative stress, as some reports suggest that dysregulated Ca2+
promotes increased formation of ROS, while others support the opposite. Prior work has
quantified several key outcome measures associated with oxidative stress in aldehyde
dehydrogenase 2 knockout (Aldh2-/-) mice, a non-transgenic model of sporadic
Alzheimer’s disease. Here, we tested the hypothesis that early oxidative stress can promote
Ca2+ dysregulation across aging by measuring Ca2+-dependent processes using
electrophysiological and imaging methods and focusing on the afterhyperpolarization
(AHP), synaptic activation, somatic Ca2+, and long-term potentiation in the Aldh2-/- mouse.
Our results show a significant age-related decrease in the AHP along with an increase in
the slow AHP amplitude in Aldh2-/- animals. Measures of synaptic excitability were
unaltered, although significant reductions in long-term potentiation maintenance were
noted in the Aldh2-/- animals compared to wild-type. With so few changes in Ca2+ and Ca2+dependent processes in an animal model that shows significant increases in HNE adducts,
Aβ, p-tau, and activated caspases across age, the current findings do not support a direct
link between neuronal Ca2+ dysregulation and uncontrolled oxidative stress.

34

2.2

Introduction
Alzheimer’s disease (AD) is a devastating condition underscored by progressive

memory loss and profound reductions in quality of life. Currently, there are no effective
disease-modifying pharmaceutical interventions, and those that are available provide only
symptomatic relief. It is estimated that 5.4 million Americans currently suffer from AD
and this number is projected to grow to 13.8 million individuals by the year 2050 [185].
Moreover, the cost of patient care is cumbersome to society, healthcare providers, and,
importantly, the families involved. Although much progress has been made in identifying
underlying causes and mechanisms, a treatment for AD, much less a cure, remains elusive.
Several dysregulated intracellular signaling pathways that participate in the
development of cognitive, as well as non-cognitive, declines have been described for
dementias, including frontotemporal, vascular cognitive impairment, and AD [379-382].
AD has been characterized by several pathological markers including amyloid-β (Aβ)
plaque deposition, neurofibrillary tangles, impaired glutamatergic and cholinergic
neurotransmission, increased production of inflammatory cytokines and oxidative stress,
as well as neuronal Ca2+ dysregulation. A number of transgenic animal models have been
developed in an attempt to recapitulate these pathological events, with the goal of
identifying how they manifest and promote disease progression [383-389]. Perhaps not
surprisingly given the complexity and etiology of the disease, few studies have provided
clarity regarding the onset of changes and the temporal associations between these
pathological events. For example, while there is strong evidence that neuronal Ca2+
dysregulation can drive oxidative stress, there is also ample evidence to support the
contrary; that is, that oxidative stress can dysregulate Ca2+ homeostasis [23, 348, 390-395].
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To address this, it is advantageous to determine the exact temporal associations between
these markers in an attempt to highlight their role in disease progression [396-400].
Oxidative stress-induced damage is critical in the pathogenesis of AD [401-403].
While this damage also occurs as part of normal aging, it appears significantly increased
in the brains of AD patients compared to age-matched elderly controls, suggesting the
involvement of additional oxidative factors in AD [404-407]. Oxidative damage can be
mediated through lipid peroxidation (LPx), protein and DNA oxidation, decreases in
mitochondrial metabolism, and increases in advanced glycation end products [408]. For
example, 4-hydroxynonenal (HNE) is a reactive aldehydic byproduct of oxidative stressinduced LPx, and increases in free HNE and HNE protein adducts have been observed in
both the brain and cerebral spinal fluid of AD patients [406, 407, 409-412]. Studies have
shown that overproduction of HNE can inhibit dephosphorylation of tau, target key
mitochondrial enzymes, alter Aβ peptide deposition, mediate cell death, reduce synaptic
processes/communication, and impair cognition [376, 413-416]. These findings squarely
position HNE as a mediator of cellular damage in oxidative stress, and perhaps also as an
initiating factor in AD pathogenesis. Early and widespread manifestation of oxidative
stress byproducts in AD patients and in AD animal models precede the development of Aβ
plaques, NFTs, and cognitive decline [417-423]. These temporal associations lead to the
formulation of the oxidative stress hypothesis of AD [401-403]. While electrophysiological
and synaptic structure/function relationships linked to oxidative stress can impact cellular
communication and throughput [333, 424-426], the onset of these changes with respect to
the manifestation of the phenotype has not been carefully characterized.
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While some studies have investigated the association between Ca2+ dysregulation
and oxidative stress, few labs have directly measured neuronal Ca2+ in the presence of
rising oxidative stress loads with aging. In the current study, we used an oxidative stressinduced model of age-related cognitive impairment with a gene deletion of ALDH2, an
enzyme important for the detoxification of endogenous aldehydes arising from LPx [376378]. This model presents with marked increases in LPx byproducts (i.e. HNE protein
adducts) from as early as 3 months of age, followed by age-related increases in Aβ,
phosphorylated tau protein (p-tau), and activated caspases, as well as by decreases in
synaptic proteins [376]. Moreover, deficits in hippocampus-dependent working and spatial
memory tasks, together with reductions in dorsal CA1 dendritic arborization and spine
density, are also present in this animal model [376, 377]. The slow, age-driven progression
of LPx byproduct accumulation highlights the model’s utility and uniqueness in
recapitulating AD phenotypes in the context of aging, and therefore represents a valuable
model of sporadic AD. Here, we sought to characterize the relationship between neuronal
Ca2+ dysregulation and oxidative stress in an animal model that overproduces HNE adducts
at an early age. We chose specific ages to frame the onset of the histopathology in the
model before (1.5 months), soon-after (4 months), and well-after (10 months) AD
pathology manifestation. Oregon Green Bapta-1 (OGB-1)-based neuronal Ca2+
fluorescence, synaptic and post-synaptic excitability, and long-term potentiation (LTP)
changes were characterized to test the hypothesis that early oxidative stress drives Ca2+
dysregulation. Only mild alterations in physiological parameters were seen. This result,
combined with small changes in Ca2+-dependent processes and LTP, do not support the
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proposal that oxidative stress in this model leads to Ca2+ dysregulation within CA1 neurons
undergoing AD-like dysfunction.

2.3

Methods
2.3.1 Animals
Aldehyde dehydrogenase 2 knockout (Aldh2-/-) mice, derived from a C57BL/6J

background and generated by a gene-targeting knockout (KO) as previously described
[427], were kindly provided by Dr. T. Kawamoto (University of Occupational and
Environmental Health, Kitakyushu, Japan). The wild-type (WT) and Aldh2-/- cohorts used
in the current study were generated by the mating of heterozygotes (obtained by
backcrossing Aldh2-/- mice with WT C57BL/6J mice for more than 10 generations) and
genotyping of the progeny using PCR analysis of genomic DNA (extracted from ear
punches) utilizing primers previously reported [428]. This process allowed the generation
of age- and gender-matched WT and Aldh2-/- littermates. Experimenters were blinded to
the genotype of the animals during all data acquisition and throughout analyses.
LTP experiments were conducted on 8-month old animals derived and maintained at
Queen’s University (Kingston, Ontario, Canada). Young-adult (1.5 months), adult (4
months), and mid-age (10 months) mice were shipped to the University of Kentucky in
several cohorts. Each cohort represented animals (male and female Aldh2-/- mice and their
WT littermates) at a particular age (e.g. 4.5 weeks, 3.5 months, and 9.5 months). As only
one animal could be recorded per day, recording for each cohort was staggered across 3-5
weeks. The average age of each cohort was 1.5, 4, and 10 months. Male mice were housed
individually while females were paired together. All animals were maintained on a 12 h
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on/12 h off light cycle and were fed Teklad Global 18% protein rodent diet ad libitum.
Routine assessment of animal health was performed by a veterinarian and animals
exhibiting signs of morbidity were excluded from the study. Treatment and handling of all
animals was in accordance with both university’s Institutional Animal Care and Use
Committee guidelines.
2.3.2 Intracellular Recordings and Ca2+ Imaging
2.3.2.1 Slice Preparation
Mice were anesthetized using inhalable isoflurane (5%) followed by decapitation. Brains
were quickly removed and incubated in ice-cold low Ca2+, high magnesium artificial
cerebral spinal fluid (ACSF): (in mM) 114 NaCl, 3 KCl, 10 glucose, 1.25 KH2PO4, 26
NaHCO3, 0.096 CaCl2 anhydrous, and 7.98 MgCl2 anhydrous. Slices (350 µm thick) from
the dorsal hippocampus were sectioned using a Vibratome® 3000 (TPI; St. Louis, MO)
and incubated for at least 2 hours at 32°C in a humidified (95% O2 – 5% CO2) interfacetype chamber in normal Ca2+ ACSF: (in mM) 114 NaCl, 3 KCl, 10 glucose, 1.25 KH2PO4,
26 NaHCO3, 2 CaCl2 anhydrous, and 2 MgCl2 anhydrous. Slices were then placed on a net
in a heated recording chamber (RC-22C; Warner Instruments, Co., Hamden, CT) at 32°C
with a TC2Bip/HPRE2 in-line heating system (Cell Micro Controls; Norfolk, VA) and
perfused (above and below the slice) with a continuous flow of oxygenated normal Ca2+
ACSF at the rate of 1.5 mL/min. Slices were visualized under a Nikon Eclipse E600FN
microscope.
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2.3.2.2 Current Clamp Electrophysiology
Sharp electrodes (~80 – 120 MΩ) were pulled from 1.0 mm diameter borosilicate
glass capillaries (World Precision Instruments, Inc.; Sarasota, FL) on a Sutter Instruments
P80 pipette puller (Novato, CA). Tips were initially backfilled with a bolus of 1.25 mM
OGB-1, pH 7.4 (ThermoFisher Scientific, Catalog number: O6806; Waltham, MA). The
rest of the electrode was filled with 1 M potassium methyl sulfate (KMeSO4) in 10 mM
HEPES. A bipolar stimulating electrode was placed on the Schaffer collaterals (SC) for
stimulation (0.1 ms duration) and the sharp electrode was slowly advanced through stratum
pyramidale of field CA1 to record primary neurons. A stimulator (SD9K, Astro Med Inc.,
Grass Instruments; Warwick, RI) was used for synaptic activation. Responses were
recorded through an AxoClamp-2B amplifier (Molecular Devices LLC.; San Jose, CA) and
digitized at ~ 5-10 KHz with a Digidata® 1550B (Molecular Devices LLC.). Data were
processed through pClamp (v10.7, Molecular Devices LLC.). While other cell types,
including interneurons and astrocytes, are present in field CA1, compactness of the
pyramidal layer, morphology of the cell imaged, and spiking properties of the cell were
used to limit our recordings to only primary pyramidal neurons.
2.3.2.3 Afterhyperpolarization (AHP)
For measures of post-synaptic excitability, cells were held at -65 mV and action
potential (AP) threshold was set to -55 mV. Four AP bursts were evoked (depolarizing 150
ms current injection) to generate the Ca2+-dependent AHP every 30 s for 5 min. Three
measures of the AHP were quantified: the medium AHP (mAHP), the slow AHP (sAHP),
and the AHP duration. The mAHP was defined as the peak hyperpolarization observed
immediately after the end of current injection. The sAHP was measured as the change in
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amplitude at 800 ms post-current injection compared to baseline. Quantification of the
AHP duration was defined as the time between peak amplitude of the AHP and the return
to baseline. We report data on 12 neurons/8 mice (1.5 months), 11 neurons/8 mice (4
months), and 11 neurons/7 mice (10 months) in the WT dataset, and on 17 neurons/15 mice
(1.5 months), 9 neurons/7 mice (4 months), and 13 neurons/6 mice (10 months) in the
Aldh2-/- dataset.
2.3.2.4 Input/Output (I/O) Curves
For measures of synaptic excitability, cells were held at -70 mV and stimulated
every 10 s. Excitatory post-synaptic potential (EPSP) amplitudes were measured from an
increasing series of activation voltages. Amplitudes were used to determine the threshold
for an AP and then plotted to generate I/O curves and their slopes. We report on data from
10 neurons/7 mice (1.5 months), 10 neurons/8 mice (4 months), and 11 neurons/7 mice (10
months) in the WT dataset, and 16 neurons/15 mice (1.5 months), 8 neurons/6 mice (4
months), and 11 neurons/6 mice (10 months) in the Aldh2-/- dataset.
2.3.2.5 Repeated Synaptic Stimulation
Synaptic stimulation intensity during repeated synaptic stimulation (RSS; 10 s, 7
Hz) was set at the threshold for an AP.

Outcome measures included synaptic

hyperpolarization and EPSP facilitation in relation to the first EPSP (baseline) in the train.
Synaptic hyperpolarization was measured as the mean peak hyperpolarization amplitudes
following the 6th through 9th EPSPs. The growth of the EPSP during the train was measured
early (EPSPs 6 through 9) and late (last four EPSPs) during RSS. We report on data from
10 neurons/7 mice (1.5 months), 10 neurons/8 mice (4 months), and 11 neurons/7 mice (10
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months) in the WT dataset, and 15 neurons/14 mice (1.5 months), 8 neurons/6 mice (4
months), and 11 neurons/6 mice (10 months) in the Aldh2-/- dataset.
2.3.2.6 Ca2+ Imaging
Cells were visualized under a 40x objective using a filter cube (Ex: 470/40 nm; Em:
525/50; Dichroic 495 nm; Chroma Technology Corp.; Bellows Falls, VT). Imaging
Workbench (INDEC BioSystems; Los Altos, CA) was used to quantify signals. A Lambda
DG-4 (Sutter Instruments; Novato, CA) was used as a source to activate the fluorophore
with exposures in the range of 250-800 ms, depending on the depth of the cell imaged.
OGB-1 dye was allowed to diffuse from the tip of the recording electrode for 10-15 min
prior to initiation of Ca2+ imaging experiments. A photometrics camera (Teledyne
Photometrics; Tucson, AZ) was used to image Ca2+ fluorescence and kinetics. Two regions
of interest (ROI) were created: one around the cell body and another of similar size in tissue
adjacent to the imaged cell. Background subtraction and normalization to baseline (ΔF/F%)
were used during analysis of OGB-1 signal. For quantification of resting fluorescence,
values were averaged before RSS and normalized to the depth of the recorded cell.
Outcome measures included rise time, peak amplitude, decay time, and area-under-thecurve (AUC) (ΔF/F %*s) during RSS and were derived using ClampFit (Molecular
Devices LLC.; San Jose, CA) and SigmaPlot (Systat Software, Inc.; San Jose, CA). Data
reported here were taken from 8 neurons/7 mice (1.5 months), 7 neurons/5 mice (4 months),
and 9 neurons/6 mice (10 months) for the WT dataset, and 8 neurons/8 mice (1.5 months),
6 neurons/5 mice (4 months), and 11 neurons/6 mice (10 months) for the Aldh2-/- dataset.
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2.3.2.7 Cell Health and Exclusion Criteria
Only neurons that fit the following criteria were included in this study: input
resistance ≥ 30 MΩ, holding current ≤ than -350 pA, and AP peak ≥ 0 mV. If the number
of APs during RSS was greater than two standard deviations (SD) from the mean, the cell
was deemed an outlier and removed from the analysis. A summary of these values is
reported in Table 1.
2.3.3 LTP Induction and Measures
2.3.3.1 Slice Preparation
Hemi-brain slices from the dorsal hippocampus were obtained from male KO and
WT mice at 8 months of age. Animals were sacrificed by decapitation, and the brain was
rapidly extracted and transferred into a slicing chamber containing ice-cold ACSF ([in
mM] 124 NaCl, 26.2 NaHCO3, 4.4 KCl, 1.3 MgSO4, 1 NaH2PO4, 2.5 CaCl2, 10 glucose,
and 19.7 mannitol; pH 7.3-7.4) saturated with carbogen (95% O2/ 5% CO2). The brain was
split into two hemispheres using a scalpel and sectioned into 400 μm transverse slices using
a vibratome (Leica VT1200s; Leica Microsystems, Concord, ON). Slices were then
transferred into a submerged incubation chamber filled with ACSF, continuously bubbled
with carbogen, maintained at 33.5°C, and allowed to recover for 2 hours prior to recording.
2.3.3.2 Extracellular Recordings
Following incubation, each slice was transferred into a submersion-type recording
chamber maintained at 32°C and continuously perfused with carbogen-saturated ACSF at
a rate of 2-3 mL/min. A concentric bipolar stimulating electrode (Rhodes Medical
instruments, Catalog Number SNE-100X; Tujunga, CA) was placed in the SC fibers, while
a glass recording electrode (tip resistance 1-2 MΩ) containing ACSF was placed within the
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stratum radiatum of area CA1 of the dorsal hippocampus. Stimulation (0.1 ms duration)
was delivered by an electrode connected to a stimulus isolation unit (FE180 Stimulus
Isolator; AD Instruments, Colorado Springs, CO, USA) providing a constant current
output. The field postsynaptic potentials (fPSPs) in CA1 were recorded with glass
electrodes referenced against an Ag/AgCl pellet in the recording chamber bath. The
recording electrode was connected to an Axopatch-200A amplifier (Molecular Devices
LLC.) and A/D converter (PowerLab 4/35 running v8 LabChart; AD Instruments),
allowing the signal to be filtered (low pass at 1 kHZ), digitized (10 kHz), and stored for
offline analysis. The signal was additionally conditioned online using the Hum Bug (Quest
Scientific, Vancouver, BC).
2.3.3.3 I/O Curves
I/O curves were established by stimulating the SC at increasing intensities (0.52.0mA in 0.1mA increments). Data reported here were taken from 15 WT and 10 Aldh2-/mice (an error was made saving the data resulting in the loss of one observation point).
Based on these curves, a stimulation intensity yielding ~50-60% of the maximal fPSP
amplitude was used for baseline and LTP induction recording.
2.3.3.4 LTP Induction
Data reported here were taken from 15 WT and 11 Aldh2-/- mice. Hippocampal
fPSPs (every 30 s) were recorded until 30 min of stable baseline was achieved (≤ 10%
difference between successive data points for fPSPs, averaged over 5 min epochs).
Subsequently, high frequency stimulation (HFS) consisting of 100 single pulses (0.1 ms at
100 Hz) per burst (pulse intensity as determined above) was delivered to the SC fibers.
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Two trains of HFS were delivered in total, with 30 s between trains. Hippocampal fPSPs
were recorded for 60 min following the second HFS episode.
2.3.3.5 Statistical Analyses
Electrophysiological and imaging data were tested for significance on main effects
of age and genotype using two-way ANOVAs (SigmaPlot; Systat Software, Inc.; San Jose,
CA). Sex differences using three-way ANOVAs (SigmaPlot; Systat Software, Inc.; San
Jose, CA) were also investigated, but are not reported here (see results). Two-way repeated
measures mixed ANOVAs (GraphPad Prism 8) were used to determine differences in the
extent of LTP in WT and Aldh2-/- mice. Greenhouse-Geisser corrections were applied
where appropriate. Student’s t-tests (unpaired) were used to investigate LTP maintenance
40-60 min after induction. For all LTP experiments, only one recording was obtained per
animal. A p value of < 0.05 was considered to be significant for all measures. All data are
reported as means ± standard error of the mean (SEM).

2.4

Results
Previous work using Aldh2-/- mice has shown little evidence of sex differences in this

KO model [376, 429]. Because statistical significance was quantitatively consistent across
the variables measured irrespective of the inclusion of sex, and because of the low number
of recorded/imaged cells in some groups, sexes were combined for measures of Ca2+ and
both pre- and post-synaptic excitability (Figures 2.1-4). Nevertheless, we present ANOVA
results on key outcome measures either with sex combined or separated by sex. LTP
measures were only conducted in male WT and KO mice (Figure 2.5).
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2.4.1 Neuronal Health Measures
Table 2.1 shows outcome measures describing neuronal health during
electrophysiological recordings and Ca2+ imaging experiments. Resting fluorescence
normalized to cell depth showed no differences across age or genotype (p > 0.05). Input
resistance and AP amplitude were unaltered across aging and genotype (p > 0.05). A
significant main effect of aging was observed on holding current measures (F (2,74) = 5.288,
p < 0.01; two-way ANOVA), however, post hoc analysis revealed this was only present in
the WT group (WT p = 0.025, Aldh2-/- p > 0.05). Additionally, a significant main effect of
aging was present in the number of APs elicited during imaging across both genotypes (F
(2,48) =

17.756, p < 0.001; two-way ANOVA). While the number of APs at 4 months was

significantly higher (stimulation setting error), this had no noticeable impact on Ca2+ levels
(Figures 4E and 4F). In fact, normalization of AUC data to the number of action potentials
triggered during activation did not alter outcomes (i.e. no significant change in Ca2+ with
age or genotype; data not shown).
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Table 2.1. Measures of Neuronal Health and Resting Fluorescence.
Action

Resting

Input
Age

Holding

Genotype

Potential

# of Action

Amplitude

Potentials

Resistance
(months)

Current (pA)
(MΩ)

(ΔF/F)

(mV)

WT

Aldh2-/-

Significance

Fluorescence

1.5

-83.3 ± 25.4

67.0 ± 5.4

12.8 ± 1.7

69.9 ± 0.1

68.6 ± 20.2

4

-182.5 ± 21.3

63.0 ± 3.3

7.3 ± 1.6

75.6 ± 0.4

51.0 ± 17.5

10

-152.7 ± 36.2

55.8 ± 4.7

11.4 ± 1.6

70.2 ± 1.3

79.2 ± 19.7

1.5

-105.6 ± 21.2

65.3 ± 4.6

11.3 ± 1.4

70.0 ± 0

73.3 ± 27.9

4

-167.8 ± 29.6

55.2 ± 4.4

9.9 ± 1.5

76.0 ± 0

63.9 ± 23.6

10

-143.8 ± 20.1

68.1 ± 4.3

7.5 ± 1.1

70.5 ± 1.5

105.8 ± 24.0

-

*p < 0.01

n.s.

n.s.

*p < 0.001

n.s.

47

Table 2.1. Measures of Neuronal Health and Resting Fluorescence. Properties of
neuronal health were compared across age and genotype. Holding current and input
resistance measures reflect plasma membrane integrity and “leakiness.” Additionally,
action potential amplitude during AHP data acquisition and the number of action potentials
during Ca2+ imaging are reported. Resting fluorescence was normalized to the depth of
each cell imaged. While a significant aging effect on holding current was seen from 1.5 to
4 months (p < 0.01), this was only present within the WT group. A main effect of age on
the number of action potentials triggered during imaging was seen (p < 0.001), however
this did not have an impact on Ca2+ (see results). Asterisks (*) represent significant main
effect of age. Numbers represent means ± SEM and “n.s.” indicates non-significance.
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2.4.2 Post-Synaptic Excitability Changes (AHP)
We characterized the Ca2+-dependent AHP in WT and Aldh2-/- animals across age
(Figure 2.1A) and identified a significant age-dependent reduction in the amplitude of both
the mAHP (Figure 2.1B; F (2,74) = 4.391, p < 0.02; two-way ANOVA) and sAHP (Figure
2.1C; F (2,74) = 5.050, p < 0.01; two-way ANOVA). A slightly larger sAHP was also present
in the Aldh2-/- group, highlighted by a main genotype effect (F (2,74) = 4.765, p < 0.04; twoway ANOVA). Despite these observations, the AHP duration remained unaltered (Figure
2.1D; p > 0.05). Of interest, a main effect of sex was also observed in the mAHP (F (2,74) =
4.141, p < 0.05; three-way ANOVA) in which female mice displayed an overall reduction
in AHP amplitude irrespective of genotype (data not shown). No significant sex differences
were present in the sAHP or AHP duration (p > 0.05). These findings suggest that a
reduction in the AHP seems to develop with age in this animal model irrespective of
genotype. Interestingly, our lab has previously shown that in 14 month old APP/PS1 mice,
a reduction in L-VGCC density is seen in CA1 neurons when compared to WT [242]. These
results differ from those seen in aging rats and rabbits where significant increases in Ca2+mediated processes (including the AHP) are typically observed [2, 8, 9]. Perhaps this
divergence is reflective of the particular genetic background in the Aldh2-/- model, and
highlights the nongeneralizable nature of the Ca2+ hypothesis of brain aging and dementia.
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Figure 2.1. AHP in WT and Aldh2-/- Mice Across Age.
A. Representative AHP following post-synaptic depolarization with 4 action potentials. B.C. A main effect of aging (p < 0.02) on the mAHP and sAHP was observed within each
genotype. A main effect of genotype was also present on the sAHP (p < 0.04). D. Measures
of the AHP duration were unaltered across aging or genotypes. We report data on 12
neurons (1.5 months), 11 neurons (4 months), and 11 neurons (10 months) in the WT
dataset, and on 17 neurons (1.5 months), 9 neurons (4 months), and 13 neurons (10 months)
in the Aldh2-/- dataset. Asterisks (*) represent significance across aging (above left and right
bars) and genotype (top horizontal bar separated by an ampersand) at p < 0.05.
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2.4.3 Synaptic Excitability
Neuronal synaptic excitability was derived from measures of I/O curves (Figure 2.2),
as well as from EPSP amplitudes during RSS (Figure 2.3). Given prior work showing
significant decreases in synaptophysin (an integral membrane protein of synaptic terminals
[376]), and reports of altered dendritic morphology in the Aldh2-/- mouse, including
reduced dendritic length and spine density [377], it is surprising that measures of neuronal
excitability (Figure 2.2B) and short-term potentiation (Figures 2.3C-E) were not
significantly different across age or genotype (p > 0.05). This could reflect the resilience
of this mouse model to significant alterations in dendritic morphology, highlight the
presence of a successful compensatory mechanism, or provide evidence that physiological
activation under relatively low frequencies is spared. Sex differences were also
investigated, but no significant differences were detected on either I/O or RSS measures (p
> 0.05; data not shown).
2.4.4 Ca2+ Imaging
Somatic Ca2+ kinetics before, during, and after RSS were compared across genotype
and age (Figures 2.4A and 2.4B). No significant alterations in Ca2+ handling were seen
(Figures 2.4C-F; p > 0.05). Given that minor, if any, changes in the AHP were present,
these results are perhaps not surprising. Indeed, larger AHPs are often associated with
increases in direct/indirect Ca2+ measures [11, 97, 106]. Sex differences were not seen on
any of the Ca2+ measures quantified (p > 0.05; data not shown).
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Figure 2.2. Extracellular Synaptic Activation.
A. Example of EPSPs recorded below and at threshold of an action potential. Inset shows
I/O plot fit from EPSP amplitudes with increasing stimulation intensity. B. Synaptic
excitability derived from I/O measures (slopes). Black dot represents the time at which
synaptic stimulation was initiated. We report on data from 10 neurons (1.5 months), 10
neurons (4 months), and 11 neurons (10 months) in the WT dataset, and 16 neurons (1.5
months), 8 neurons (4 months), and 11 neurons (10 months) in the Aldh2-/- dataset. Results
showed no differences across genotype or age (p > 0.05).
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Figure 2.3. Repeated Synaptic Stimulation (RSS).
A. Example of RSS showing EPSP potentiation and synaptic hyperpolarization. B. Upward
arrows illustrate growth in EPSP amplitude during repeated activation (7 Hz for 10 s),
while downward arrows show increased amplitude in the synaptic hyperpolarization.
Action potentials were truncated for illustration. C.-E. Synaptic hyperpolarization
measured during RSS and EPSP facilitation taken during the first (early) and last (late)
periods of RSS. Black dots represent the time at which synaptic stimulation was initiated.
We report on data from 10 neurons (1.5 months), 10 neurons (4 months), and 11 neurons
(10 months) in the WT dataset, and 15 neurons (1.5 months), 8 neurons (4 months), and 11
neurons (10 months) in the Aldh2-/- dataset. No differences in synaptic hyperpolarization,
early EPSP facilitation, or late EPSP facilitation were detected across age or genotype (p >
0.05).
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Figure 2.4. Changes in OGB-1 Fluorescence During 10 s RSS.
A. Example of an imaged neuron loaded with OGB-1. B. Normalized fluorescence change
across time (% ΔF/F) before, during, and after synaptic stimulation in the cellular
compartment (dark line) and in the extracellular space adjacent to the cell (gray line). C.F. Measures of Ca2+ kinetics (rise and decay time) and somatic Ca2+ levels (peak amplitude
and AUC). Data reported here were taken from 8 neurons (1.5 months), 7 neurons (4
months), and 9 neurons (10 months) for the WT dataset, and 8 neurons (1.5 months), 6
neurons (4 months), and 11 neurons (10 months) for the Aldh2-/- dataset. No significant
differences across age or genotype were detected (p > 0.05).
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2.4.5 Long-term Synaptic Plasticity Changes
The slope of fPSPs recorded in dorsal CA1 of WT and Aldh2-/- mice increased with
higher stimulation intensities (F(1.827, 42.02) = 166.2, p < 0.0001; two-way repeated measures
mixed ANOVA); however, no significant effects were noted (Figure 2.5A; p > 0.05),
highlighting a lack of difference in excitability between the two groups. LTP changes were
measured following a robust LTP induction protocol in a subset of mid-age (8 months)
male mice. While no main effect of genotype was detected on measures of fPSP slopes
across the multiple phases of LTP induction and maintenance (Figure 2.5B; p > 0.05),
analysis of the data during the maintenance phase of LTP (the last 20 min) revealed a
significant genotype effect with greater fPSP slopes in WT (201 ± 5%) compared to Aldh2/-

mice (180 ± 5%; t = 16.84, p < 0.0001; unpaired t-test). Perhaps the use of a strong

protocol for LTP induction (2X 100 Hz) masked differences in the initial phases of the
potentiation.
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Figure 2.5. LTP Outcomes.
A. I/O curves for fPSP slopes (mV/ms; mean ± SEM) elicited in CA1 by single pulse
stimulation of the SC in WT and Aldh2-/- mice. The fPSP slope increased with higher
stimulation intensities, but no statistical differences between the two groups were detected
(p > 0.05). B. fPSP slope (mV/ms; mean ± SEM; normalized to baseline) before and after
HFS (arrow) in WT and Aldh2-/- mice. Delivery of HFS reliably increased the fPSP slope,
however no main effect of genotype was detected (p > 0.05). Data reported here were taken
from 15 WT and 11 Aldh2-/- mice for LTP induction and 15 WT and 10 Aldh2-/- mice for
I/O curves. Analysis of the maintenance phase of LTP (the last 20 min) revealed a
significant genotype effect with somewhat reduced potentiation in the Aldh2-/- animals (t =
16.84, p < 0.0001; unpaired t-test). Asterisks (*) represent significant group fPSP slope
differences at specific time points (t-test) at p < 0.05. Insets depict typical fPSP before
(smaller downward deflection) and after (larger downward deflection) HFS in WT (top)
and Aldh2-/- mice (bottom; calibration is 0.5 mV and 5 ms).
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2.5

Discussion
Measures of Ca2+-dependent potentials in single neurons are a historically-reliable

method of indirectly detecting alterations to Ca2+ homeostasis. Indeed, changes in the AHP
with aging reflect Ca2+ channel density and function, as well as Ca2+ buffering and
signaling [80, 97, 103, 161, 430]. In this study, we measured Ca2+-related processes in
Aldh2-/- and WT mice at different ages in order to draw temporal associations between
dysregulated Ca2+ and age-mediated increases in oxidative stress byproducts. Based on
previous literature thoroughly characterizing the onset of both behavioral and cellular
biomarkers, we hypothesized that in this sporadic model of AD with uncontrolled oxidative
stress, early oxidative stress could promote Ca2+ dysregulation. To our surprise, however,
Ca2+-dependent processes were largely unaltered. Further, while age-dependent reductions
in the mAHP and sAHP were present, alterations in synaptic processes (both short-term
and long-term), as well as Ca2+ kinetics, remained relatively unchanged. However, we did
note the presence of a small, albeit significant, reduction in LTP maintenance in the Aldh2/-

animals compared to WT.
In this animal model, behavioral deficits are present as early as 3.5 (novel object

recognition and Y-maze) or 6 months of age (Morris water maze) [376]. Aβ and p-tau
accumulation is significant by 6 months, while HNE adducts and several caspases are
clearly elevated by 3 months when compared to controls. Our analysis of Ca2+-dependent
processes at early time-points (1.5-4 months) does demonstrate a significant reduction in
the mAHP and sAHP. However, given that the mAHP and sAHP were reduced in both the
WT and the Aldh2-/- groups with age, we cannot dissociate the effect of aging from that of
the genetic manipulation. While there has been some evidence of genotype-mediated
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reductions in Ca2+ processes in animal models of AD [242, 348], it is surprising that a
significant age-dependent reduction in the AHP was present here. Given the importance of
the genetic backgrounds in animal models and their impact on physiological processes
[431-435], it is likely that this particular mouse model, irrespective of the ALDH2
manipulation, presents with a reduction in the AHP across age, thus reflecting on the nongeneralizable nature of neuronal Ca2+ dysregulation with age across AD models. Previous
work from different labs has reported no loss of hippocampal neurons as well as similar
levels of synaptic proteins in behaviorally-impaired aged animals compared to young
counterparts [432, 433, 436]. Perhaps the mechanism underlying the age-dependent
reduction in the AHP presented here in both the WT and Aldh2-/- groups is dependent on
the genetic background of the animals, and may highlight an increase in the resilience of
the animal to the impact of elevated HNE adducts. Overall, however, it does not appear
that the presence of a greater LPx burden specifically induces Ca2+ dysregulation. While
the electrophysiological phenotype and outcome measures were only minimally affected,
several potential mechanisms are discussed.
Firstly, in the current study, animals may not have been exposed to sufficient
cumulative oxidative stress to alter neurophysiological properties. No electrophysiological
studies investigating the Aldh2-/- mouse at more mature ages (i.e., 18 months) have been
published. Nevertheless, evidence from other models of AD does suggest a worsening of
the phenotype with age. Indeed, while there is a paucity of aging studies characterizing
Ca2+-mediated AD phenotypes at much later ages, a significant age-dependent increase in
hippocampal L-VGCC density and AHP amplitude has been reported in transgenic AD
mouse models at 12-18 months of age [127, 241]. Given that our work specifically
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addresses alterations in Ca2+ homeostasis in a sporadic model of AD, it is not clear how
these changes align with prior literature that has commonly used transgenic models of
familial AD. Thus, it is possible that the Aldh2-/- mouse presents with mild
electrophysiological alterations during early to mid-life that worsen with more advanced
age. Alternatively, the use of a ‘2-hit’ model could unmask more robust changes at a
younger age in this particular model, as previous evidence has demonstrated the
effectiveness of using a secondary insult in models of traumatic brain injury (TBI),
Parkinson’s disease, and even schizophrenia to detect complex or less-sensitive processes
[437-440]. In fact, a previous study using this animal model in combination with mild
(TBI) recently reported significant increases in inflammatory cytokines, as well as
sustained cognitive deficits, when compared to sham controls [441]. In this work,
administration of anti-inflammatory agents post-TBI ameliorated both inflammatory and
cognitive impairments of the Aldh2-/- mice.
Moreover, reports conducted in the dorsal hippocampus of Aldh2-/- mice have
highlighted morphological changes in this area only, with no alterations detected in the
ventral hippocampus or primary sensory cortex [377], suggesting that the impact of
oxidative stress may be region-selective. In this animal model, the dissociation between
the poor behavioral phenotype and the paucity of Ca2+-mediated electrophysiological
changes in the hippocampus support the notion that brain regions other than the
hippocampus can also participate in the encoding, storing, and recalling of memory
processes [442-446]. Further, the location of the KCa AHP channels is important to
consider. KCa channels, which are critical to neuronal repolarization and the AHP, have
been mostly identified in the somatodendritic region of pyramidal neurons [447-451].
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Thus, it is possible that recordings of mostly somatic potentials using the sharp electrode
technique did not permit identification of synaptic changes in dendritic spines or finer
processes negatively impacted in the Aldh2-/- model [377]. Finally, the possibility that the
genetic manipulation may have induced a series of compensatory cellular events including
increases in Ca2+ buffering, mitochondrial metabolism, or changes in the location and
density of Ca2+ or K+ channels, should be considered. Future studies investigating these
potential mechanisms are clearly needed.
With respect to the small, albeit significant, reduction in LTP in the Aldh2-/- mouse,
it is possible that the robust induction protocol used here may have thwarted more subtle
differences in synaptic plasticity. Previous evidence has shown that age-related deficits in
LTP induction were only seen when less robust (perithreshold) stimulation protocols were
used [51, 452-455]. Future studies investigating Ca2+ dysregulation across different cell
types and brain regions at more advanced ages in this animal model should be initiated to
better characterize the potential impact of oxidative stress on behavioral outcomes. In
summary, with so few changes in Ca2+ and Ca2+-dependent processes detected in an animal
model with significant increases in HNE adducts, Aβ, p-tau, and activated caspases across
age, the current findings do not support a direct link between neuronal Ca2+ dysregulation
and uncontrolled oxidative stress.

62

2.6

Acknowledgments
This work was supported by NIH grants R01AG058171 (OT and BMB) and T32

AG05461 (AOG), Canadian Institutes of Health Research grant PJT 153013 (BMB), Heart
and Stroke Foundation of Canada grant G-19-0024266 (RDA), and National Science and
Engineering Research Council grant RGPN/04624-2017 (RDA).

2.7

Conflict of Interest/Disclosure Statement
The authors have no conflict of interest to report.

63

CHAPTER 3. THE SPORADIC AND FAMILIAL AD MOUSE MODELS
3.1

Aldh2-/- Study Results
The work in Chapter 2 explored the utility of a nontraditional model of sporadic

AD (sAD), the Aldh2-/- mouse, as a way of further characterizing the relationship between
oxidative stress and Ca2+ dysregulation with aging. Previous evidence has shown that in
the Aldh2-/- mouse model, knockdown of the ALDH2 gene elicits a significant
accumulation of lipid peroxidation byproduct 4-hydroxynonenal (HNE) by 3 months of
age and remains elevated throughout life [376]. This early elevation of HNE warrants a
progressive increase in phosphorylated tau, Aβ, and caspases 3 and 6, while concurrently
reducing synaptic strength markers synaptophysin, total CREB, and PSD-95. Additionally,
considering the wealth of literature supporting the proposal that HNE has a role as an
initiating factor in AD pathogenesis [406, 407, 410, 411, 456-459], as well as the
observation of an impaired performance in learning and memory tasks by 6 months of age
[376], the Aldh2-/- mouse is positioned as a unique model for studying AD-like pathology
without the genetic manipulation of APP or PSEN genes. Despite a wide range of
phenotypes characterized in the Aldh2-/- mouse model, a lack of reporting on direct and
indirect neuronal Ca2+ markers was apparent. Thus, in collaboration with Queen’s
University, we sought to characterize measures of neuronal Ca2+ handling in alignment
with similar ages previously studied.
The relationship between Ca2+ dysregulation and oxidative stress in aging and AD
is complicated, as each have been proposed as initiating elements in AD pathogenesis while
also having been shown to promote one another when one is increased [460-466]. Indeed,
if oxidative stress propagates the dysregulation of Ca2+ then the knockdown of the
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regulatory ALDH2 gene from birth would ideally result in changes pertaining to Ca2+ and
Ca2+-mediated processes. However, much to our surprise, few changes in Ca2+ handling
were detected as the animals aged. Given both Aβ and phosphorylated tau are present in
Aldh2-/- mice [376] and that a recent morphometric characterization of this model has
shown deleterious alterations to the dendritic morphology of dorsal and ventral CA1
pyramidal neurons [376, 377], it is difficult to address the lack of Ca2+ changes here. Even
if this was evidence to disprove a relationship between oxidative stress and Ca2+
dysregulation, surely the well-documented ties between Ca2+ and Aβ [218, 220, 221], Ca2+
and phosphorylated tau [467-469], and Ca2+ and synaptic dysfunction [55, 56, 165] would
have manifested into a Ca2+-related alteration of some capacity. Perhaps a compensatory
alteration of Ca2+ binding proteins or plasma membrane/ER Ca2+ channel density or
function could explain the lack of Ca2+ changes, but only additional experimentation can
truly address this. Additional insights regarding the lack of Ca2+ alterations are discussed
in Chapter 2.5. Nevertheless, these findings underscore a lack of consistency in aging and
AD models’ phenotypic expression as mentioned in Chapter 1, highlight the complexity
of AD progression, and emphasize the necessity of using a wide range of models to
elucidate underlying mechanisms of AD development and pathogenesis.

3.2

Mouse Models of AD
3.2.1 The Utility of Mouse Models
Since the synthesis of the first transgenic mouse model by virologist Rudolph

Jaenisch in 1974 [470], the use of genetically modified animals in basic research has
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radically changed how scientists study disease states. Transgenic mouse models are
typically developed through the introduction of complementary DNA with a transgene to
the pronucleus of a zygote and then subsequently implanted into a pseudopregnant dam for
gestation [471, 472]. Animal research models provide investigators with high throughput
information on physiologic measures in controlled environments. Such data is invaluable
to identifying biological nuances at molecular, cellular, histological, and behavioral levels.
Further, as these are living organisms, intrinsic biological variables such as aging, sex, and
circadian rhythm can be measured and accounted for when genetically modifying mice.
Homologous genes between rodents and humans can lead to translatability of data that
bolster advancements in novel therapeutics. It has been through the utilization of
genetically modified mice of AD that researchers have learned more about the precipitation
of AD hallmarks during aging and in alignment with physiology. Moreover, the
identification of the APP and PSEN genes and their involvement in AD progression has
been instrumental to developing better models that adequately recapitulate AD-like
pathology [473-477].
3.2.2 AD-like Pathology in Mouse Models
With over 100 models of AD-like pathology available for commercial use [478],
the decision of selecting the right one for experiments can be challenging. Adding to this
cumbersome endeavor is the lack of a perfect AD surrogate amongst many established
models (i.e. it is incredibly difficult and complex to produce rodent offspring with desired
genetic modifications that mimic all AD neuropathology) [471, 478]. Thus, generally a
mouse model will not exhibit all of the classic hallmarks of AD pathogenesis (Aβ, tau,
neurodegeneration such as atrophy and neuronal loss, etc.). Since the development of the
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first successful mouse of amyloidogenesis [479], dozens of subsequent models have been
designed to mutate the APP gene at various sites that recapitulate APP processing through
the β- and γ-secretase pathway in a time- and concentration-dependent manner that mimics
human AD. Despite this, while low concentrations of hyperphosphorylated tau have been
detected in some of these models, characteristic neurofibrillary tangles of human AD are
seldom present, if at all [480]. The same can be said for many other models exhibiting
tauopathies or neurodegeneration, but other hallmarks like Aβ amyloidosis or neuronal loss
may not be present [478]. This has led researchers to investigate alternative methods to
recapitulate AD pathology such as viral vector transgenesis through lentivirus and adenoassociated virus techniques [471, 478, 481-483].
3.2.3 Viral Gene Delivery for Modelling AD
Viral gene delivery or transgenesis is an effective tool for eliciting region-specific
long-term transgene expression. In AD, amyloid and tau pathologies have been
recapitulated in both rat and mouse models using these techniques, although APP mutations
have yielded considerably less success in amyloidogenesis [478]. The use of viral
transgenesis can be advantageous as it is cheaper than germline modifications, allows for
neuronal projection analysis of specific brain regions, and can be used in young or aged
animals. However, like using genetic modification, virus gene therapy has drawbacks that
limit its application. Limitations such as brain injury from stereotaxic injection, the finite
packaging size of a viral vector, and occasional difficulty with genomic integration require
important consideration when planning experiments [471, 478]. Nevertheless, the growing
optimization of these techniques will surely cultivate novel and safer application methods
that promote AD-like pathological progression in animal models in future studies.
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3.2.4 Sporadic and Familial AD Mouse Models
As previously mentioned in Chapter 3.2.2, the development of many AD mouse
models stems from the identification of the APP and PSEN genes, and the ability to
promote amyloidogenesis in a mouse [479]. Importantly, APP and PSEN are two genes
known to promote familial AD (fAD), which represents only 5% of total AD cases, while
the remaining 95% are sporadic cases [185]. However, despite this disproportion within
total cases, sAD mouse models are less frequently used in research. As environmental,
lifestyle, and genetic modifying factors are key components that define sAD, it is important
that these aspects are included into a sAD model design. Naturally, these are difficult to
recapitulate into a model using a reproducible design that also elicits AD pathology.
Though the Aldh2-/- model in Chapter 2 may not rely on environmental or lifestyle
alterations to warrant AD development and progression, the early generation of lipid
peroxidation byproduct HNE and subsequent AD hallmarks without influencing the APP
or PSEN genes positioned the model as being amenable to study.
Despite selecting the Aldh2-/- mouse for experimentation, it is important to once
again note that the perfect AD surrogate has yet to be identified. While a great host of
information can be acquired by studying AD through the lens of the Aldh2-/- model, it too
has limitations. For example, like many models, the Aldh2-/- mouse does not form
neurofibrillary tangles, but only concentrations of phosphorylated tau [376]. Considering
the well-established evidence that increased neurofibrillary tangle density correlates with
reduced cognition in human AD [484-489], a model devoid of true neurofibrillary tangles
could be perceived as a shortcoming. Further, Aβ peptides both monomerize and
oligomerize in Aldh2-/- mice, but do not form amyloid deposits [376]. With consideration
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of the immense amount of literature highlighted in Chapter 1 showing Ca2+ changes with
aging and AD, and the few Ca2+ changes observed here, this may be a limitation as well.
Nevertheless, alongside increases in HNE, Aβ, and p-tau, the presence of irregularities in
synaptic proteins and cognitive impairment support use of this model to study sAD.
Irrespective of the Aldh2-/- mouse’s utility to study sAD, we decided it was of interest to
make a direct comparison of our findings to a model of fAD. As many fAD models possess
pathological features that are useful markers for studying age-dependent changes in both
neuronal and behavioral aspects, we decided to look at similar outcome measures of Ca2+
dysregulation in the 5xFAD mouse.

3.3

The 5xFAD Familial Model of AD
The decision to use the 5xFAD mouse in our second study was due to the model’s

reliable manifestation of many AD-like pathologies in an age-dependent manner. Through
genetic manipulation of 3 APP and 2 PSEN1 mutations, 5xFAD mice on a C57BL6 genetic
background exhibit extracellular amyloid deposits by 2 months [490], synaptic deficits at
2-3 months [491], and spatial working memory impairment between 3 and 6 months of age
[492]. Like many other transgenic fAD models, 5xFAD mice do not develop any
neurofibrillary tau tangles during aging. Importantly, only a few studies have reported
indirect Ca2+-related changes in the 5xFAD mouse [294, 348, 493, 494]. An increased
afterhyperpolarization was noted in 8-month old 5xFAD mice compared to WT using the
whole-cell patch clamp technique and a strong (25 action potentials) post-burst stimulation
protocol [294]. However, a reduction in the AHP and L-VGCC function has also been
observed in 2-month old 5xFAD mice compared to WT littermates [348]. Additionally, a
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reduction in calretinin and parvalbumin-positive interneurons has been noted in the
hippocampi of 12-month old 5xFAD mice [493], while 8-month old 5xFAD mice had
elevated expression of calcineurin-dependent transcription factor nuclear factor of
activated T cells 4 compared to WT [494]. Despite these inconsistent observations, no
direct measures of neuronal Ca2+ have been measured in the 5xFAD model. In
collaboration with the University of Michigan, we sought to characterize Ca2+ and Ca2+mediated processes during aging in a re-established design of the 5xFAD mouse model
using sharp electrode electrophysiological and Ca2+ imaging techniques.
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The following manuscript was accepted for publication at the Journal of Alzheimer’s
Disease. 5xFAD mouse colonies were maintained at the University of Michigan via the lab
of G.G. Murphy and managed by R. Parent. Mice were shipped to the University of
Kentucky in several cohorts. All electrophysiological recordings and Ca2+ imaging
experiments were performed by A.O. Ghoweri through the guidance of O. Thibault and
J.C. Gant. Morris water maze behavior experiments were done by L. Ouillette under the
guidance of G.G. Murphy. Amyloid plaque staining and quantification was performed by
S. Moore. Manuscript writing and editing was established by A.O. Ghoweri, O. Thibault,
H.N. Frazier, S. Moore, and G.G. Murphy. The purpose of the following study was to
characterize neuronal Ca2+ dysregulation before, during, and after the generation of
amyloid plaques in a re-established design of the 5xFAD mouse. The classic 5xFAD mouse
model of familial AD was first derived by Oakley and colleagues in 2006 to recapitulate
Alzheimer’s disease-like phenotypes through 5 genetic mutations of the APP, PS1, and
PS2 genes [495]. Though this model has provided valuable insights to the understanding
of intracellular mechanisms involved with Aβ plaque generation, the fast-paced nature of
amyloidogenesis by 2 months of age in the original 5xFAD design may have masked the
characterization of important phenotypes preceding plaque development. Thus, our
collaborators at the University of Michigan crossed hemizygous 5xFAD mice with WT
C57BL/6Tac mice to generate 5xFAD mice that exhibit AD-related pathology and
cognitive deficits 2-4 months later than the original design. We hoped that by measuring
neuronal Ca2+ handling across age, sex, and genotype in this new 5xFAD design with
slower amyloidogenesis, we could potentially elucidate subtle Ca2+-mediated markers that
participate in AD pathology progression.
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CHAPTER 4. ELECTROPHYSIOLOGICAL AND IMAGING CALCIUM
BIOMARKERS OF AGING IN MALE AND FEMALE 5XFAD MICE
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4.1

Abstract
In animal models and tissue preparations, Ca2+ dyshomeostasis is a biomarker of

aging and Alzheimer’s disease that is associated with synaptic dysfunction, neuritic
pruning, and dysregulated cellular processes. It is unclear, however, whether the onset of
Ca2+ dysregulation precedes, is concurrent with, or is the product of pathological cellular
events (e.g. oxidation, amyloid-β production, and neuroinflammation). Further, neuronal
Ca2+ dysregulation is not always present in animal models of amyloidogenesis, questioning
its reliability as a disease biomarker. Here, we directly tested for the presence of Ca2+
dysregulation in dorsal hippocampal neurons in male and female 5xFAD mice on a
C57BL/6 genetic background using sharp electrodes coupled with Oregon-green Bapta-1
imaging. We focused on 3 ages that coincide with the course of amyloid deposition: 1.5,
4, and 10 months old. Outcome variables included measures of the afterhyperpolarization,
short-term synaptic plasticity, and Ca2+ kinetics during synaptic activation. Quantitative
analyses of spatial learning and memory were also conducted using the Morris water maze.
Main effects of sex, age, and genotype were identified on measures of electrophysiology
and Ca2+ imaging. Additionally, measures of resting Oregon-green Bapta-1 fluorescence
showed significant reductions in the 5xFAD group compared to controls. Deficits in spatial
memory, along with increases in Aβ load, were detectable at older ages, allowing us to test
for temporal associations with the onset of Ca2+ dysregulation. Our results provide
evidence that reduced, rather than elevated, neuronal Ca2+ is identified in this 5xFAD
model and suggests that this surprising result may be a novel biomarker of AD.
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4.2

Introduction
The rise in Alzheimer’s disease (AD) cases is predicted to reach exponential numbers

by the year 2050, yet few, if any, new effective therapeutic drugs are currently available.
Further, the cost of care is burdensome for families and healthcare providers [185],
resulting in an urgent need for the development of new treatment strategies. While several
cellular alterations have been identified as key contributors to the onset and progression of
AD, including amyloid-β (Aβ) deposits, apolipoprotein E status, tau tangles, oxidative
stress, neuroinflammation, and synaptic loss [496-502], it is imperative to look beyond
these for new biomarkers. One target that has received considerable interest is neuronal
Ca2+ dysregulation.
The hypothesis of brain aging and AD has provided evidence that neuronal Ca2+ is
dysregulated and can negatively impact neuronal health, network communication, and
synaptic plasticity [1-4, 503-506]. In the hippocampus, a structure necessary for spatial
mapping and short-term memory, an altered network fraught with reduced synaptic
plasticity [18, 507, 508], increased pruning [509-512], and recent evidence of hyperactivity
[336, 513] is likely to mediate cognitive and memory impairments [338, 514-523]. The
role that neuronal Ca2+ assumes with respect to these processes is unclear, as Ca2+
dysregulation may occur when Ca2+ is elevated or decreased, during states of rest or during
synaptic activation, or as the consequence of alterations in synaptic communication. Given
the variability in Ca2+ homeostasis measures in normal aging, it is important to measure
Ca2+ in models of AD as well.
Critical mechanistic insights regarding Ca2+ dysregulation have been gained in AD
animal models [183, 274, 345, 393, 502, 524-527]; however, few studies have investigated
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this AD-associated Ca2+ dysregulation alongside aging. Initial studies of the associations
between Aβ and Ca2+ homeostasis, including the impact of Ca2+ on Aβ production, were
mostly conducted in vitro (i.e. human cell lines or animal cell culture) [reviewed in 284].
With the exception of a few culture studies conducted in adult tissues [275, 282, 528-530],
most of this early work used primary neuronal cultures derived from neonatal pups, which
prevented the inclusion of the aging component. When investigating Ca2+ dysregulation
and its physiological impact either directly (using Ca2+ imaging techniques) or indirectly
(using electrophysiological techniques), nearly all measures were obtained from AD
animals at single timepoints between the ages of 4 weeks and 12 months [281, 289-300,
512]. Although these studies highlighted increases in resting or stimulated Ca2+ levels,
triggered either synaptically or via the activation of inositol 1,4,5-trisphosphate or
ryanodine receptors, few have specifically investigated the impact of AD-associated Ca2+
dysregulation during the progress of aging [127, 241].
Stutzmann and colleagues examined Ca2+ changes across age (1.5, 6, and 18
months) in three transgenic mouse models (PS1KI, 3xTg, and APPSweTauP301L). While
enhanced endoplasmic reticulum (ER) Ca2+ signaling was observed in the PS1KI and 3xTg
models, presumably due to the PS1 mutation, this effect was not found to be age-dependent
[127]. However, similar to early aging studies [2, 9, 182], the Ca2+-mediated
afterhyperpolarization (AHP) was larger with aging, but remained unaltered across
genotype. In another study, L-type voltage-gated Ca2+ channel (L-VGCC) density was
measured across age (1, 6-9, and 12-16 months) in wild-type (WT) and 3xTg mice [241].
L-VGCC density was significantly increased at 12-16 months in the transgenic mice
compared to WT littermates. Surprisingly, however, no significant increase in these
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measures were found across age in WT animals at 12-16 months. This contradicts previous
findings in the F344 rat model of aging, which showed elevations at 23-26 months of age
[97].
The paucity of direct Ca2+ measures in aged AD animal models is partly due to the
identification of human amyloid β precursor protein and presenilin (PS) mutations, which
increase production of amyloidogenic proteins from birth, resulting in the development of
a very aggressive phenotype, precluding studies in older animals. Further, besides humans
and dogs, other animal models do not develop AD phenotypes (e.g. Aβ deposition, tau
tangles). Additionally, it has been difficult to draw comparisons between pathological
aging and AD, as the former lacks clear biomarkers (i.e. Aβ plaques, tau tangles, “leaky
channels” of the ER, and enhanced neuronal death) that differentiate the disease from
normal brain aging. Furthermore, recapitulating these phenotypes in transgenic animals
does not necessarily clarify whether Ca2+ dysregulation impacts AD pathology or vice
versa.
These difficulties, together with recent evidence that Ca2+ signals appear to
decrease in two animal models of AD [242, 348], highlight the possibility that
methodological differences may mediate these discrepancies. Interestingly, previous work
by our group has shown a significant reduction in L-VGCC density in 14-month-old 2xTg
mice compared to WT using the dissociated “zipper” hippocampal slice technique [242].
Using the same methods, however, a two-fold increase in L-VGCC density was found in
aged F344 rats compared to young animals [97]. In a more recent study, we identified a
significant decrease in the AHP of 2-month-old 5xFAD mice on a C57BL/6 genetic
background compared to WT [348]. Further, in a 2008 comprehensive review of Ca2+
76

dysregulation in AD across 32 studies performed in both cell lines and mouse models with
PS mutations [525], over 100 measures of Ca2+ were identified. Of these, 24 showed
enhanced Ca2+ release from the ER while 21 exhibited decreased release. Moreover, 17
measures of plasma membrane Ca2+ influx were downregulated, two were upregulated, and
five showed no change across genotypes. Thus, while the field has argued that Ca2+
dysregulation may be a unifying mechanism that impacts aging and AD in similar ways,
this over-simplification may have hindered, rather than helped, the advancements made on
this topic.
To better characterize these processes in AD animal models in the context of aging,
we tested for the presence of Ca2+ dysregulation in the 5xFAD mice on a C57BL/6 genetic
background at three distinct ages using two techniques that have reliably identified key
biomarkers of aging across labs [2, 531, 532]. This approach allowed us to address the
onset of the Ca2+ dysregulation using both direct (Ca2+ imaging) and indirect
(electrophysiology) measures. Given that aging is the number one risk factor for AD, we
chose to utilize this 5xFAD mouse model on a congenic C57BL/L genetic background, as
these animals display a slower development of the AD phenotype [490, 533], allowing the
aging processes to participate in disease progression. Sharp electrode electrophysiology
and Oregon-green Bapta-1 (OGB-1) Ca2+ imaging were used to measure neuronal
physiology and corresponding Ca2+ changes. Behavioral characterization using the Morris
water maze (MWM) and Aβ deposition (BTA-1) was quantified to characterize phenotypic
progression. Based on our prior results, we hypothesized that contrary to what is seen in
normal aging, somatic Ca2+ would be reduced over time in this 5xFAD transgenic model
of amyloidogenesis.
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4.3

Methods
4.3.1 Animals
Young-adult (1.5 months), adult (4 months), and mid-age (10 months) male and

female 5xFAD mice and their WT littermates were derived at the University of Michigan
(Ann Arbor, MI) and shipped to the University of Kentucky (Lexington, KY) in several
cohorts of 10-20 animals. The 5xFAD mice [495] were originally obtained from the Mutant
Mouse Regional Resource Facility (MMRC) on a C57BL/6J background (stock # 034848JAX). Hemizygous 5xFAD mice were crossed with WT C57BL/6Tac mice and maintained
at the University of Michigan on this background since late 2012 (20+ generations). A
recent report suggests that 5xFAD mice on a C57BL/6 background exhibit AD-related
pathology and cognitive impairments approximately 2-4 months later than the mice
originally described by Oakley and colleagues, which utilized mice on a hybrid B6/SJL
genetic background [495, 533]. Typically, a cohort represented animals at a particular age
(e.g. 4.5 weeks, 3.5 months, and 9.5 months). Because only one animal could be
electrophysiologically recorded per day, data acquisition for each cohort was staggered
across 3-5 weeks; thus, the average age of each cohort was 1.5, 4, and 10 months.
4.3.2 Housing
While at the University of Michigan, the mice were same-sex housed in groups of
three to five, with a 14 h on/10 h off light/dark cycle, an ambient temperature of 20–22°C,
and ad libitum access to food and water. Upon transfer to the University of Kentucky, mice
were housed in a quarantined facility for a minimum of one week prior to experimentation.
Male mice were housed individually while females were paired. All animals were
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maintained on a 12 h on/12 h off light/dark cycle and fed a Teklad Global 18% protein
rodent diet ad libitum. Routine assessment of animal health was performed by a
veterinarian at both institutions and animals exhibiting signs of morbidity were excluded
from the study. Treatment and handling of all animals were performed in accordance with
each university’s Institutional Animal Care and Use Committee guidelines.
4.3.3 Slice Preparation
Mice were anesthetized using aerosolized isoflurane (5%) followed by rapid
decapitation. Brains were quickly removed and incubated in ice cold low Ca2+, high
magnesium artificial cerebrospinal fluid (ACSF) [in mM]: 114 NaCl, 3 KCl, 10 Glucose,
1.25 KH2PO4, 26 NaHCO3, 0.096 CaCl2 anhydrous, and 7.98 MgCl2 anhydrous. Threehundred and fifty µm thick slices from the dorsal hippocampus were obtained using a
Vibratome® 3000 (TPI; St. Louis, MO) and incubated for at least 2 h at 32°C in a
humidified (95% O2 – 5% CO2) interface-type chamber in normal Ca2+ ACSF [in mM]:
114 NaCl, 3 KCl, 10 Glucose, 1.25 KH2PO4, 26 NaHCO3, 2 CaCl2 anhydrous, and 2 MgCl2
anhydrous. Slices were then placed in a recording chamber (RC-22C; Warner Instruments,
Co., Hamden, CT) heated to 32°C with a TC2Bip/HPRE2 in-line heating system (Cell
Micro Controls; Norfolk, VA) and perfused with a continuous flow of oxygenated, normal
ACSF at a rate of 1.5 mL/min. Slices were then visualized under a Nikon Eclipse E600FN
microscope.
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4.3.4 Electrophysiology
Sharp electrodes (~80 – 120 MΩ) were pulled from 1.0 mm diameter borosilicate
glass capillaries (World Precision Instruments, Inc.; Sarasota, FL) on a Sutter Instruments
P80 pipette puller (Novato, CA). Electrode tips were first backfilled with a bolus of 1.25
mM OGB-1, pH 7.4 (ThermoFisher Scientific, Catalog number: O6806; Waltham, MA),
while the rest of the electrode was filled with a 1 M potassium methyl sulfate (KMeSO4)
in 10 mM HEPES. A bipolar stimulating electrode was placed on the Shaffer collaterals
and the recording electrode was slowly guided through stratum pyramidale of area CA1.
An SD9K stimulator (Astro Med Inc., Grass Instruments; Warwick, RI) was used to
synaptically stimulate the tissue slice. Responses were obtained through an AxoClamp-2B
amplifier (Molecular Devices LLC.; San Jose, CA) and digitized at ~ 5-10 KHz using a
Digidata® 1550B (Molecular Devices LLC.; San Jose, CA). Data was processed using
pClamp 10.7 software (Molecular Devices LLC.; San Jose, CA).
4.3.4.1 Afterhyperpolarization
For measures of post-synaptic activation, cells were held at -65 mV. Action
potential (AP) threshold was set to -55 mV, and 4 AP bursts were evoked (depolarizing
150 ms current injection) to generate the Ca2+-dependent AHP every 30 s for five min.
Three measures of the AHP were quantified including the medium AHP (mAHP), slow
AHP (sAHP), and AHP duration. The mAHP was defined as the peak hyperpolarization
observed immediately after the end of the current injection. The sAHP was measured as
the change in amplitude (compared to baseline) 800 ms post-current injection.
Quantification of the AHP duration was defined as the time between peak amplitude of the
AHP and the return to baseline. Here, we report data from 11 neurons (♂=6, ♀=5)/7 mice
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(♂=4, ♀=3) (1.5 months), 14 neurons (♂=6, ♀=8)/10 mice (♂=5, ♀=5) (4 months), and 13
neurons (♂=9, ♀=4)/9 mice (♂=7, ♀=2) (10 months) in the WT dataset, and 21 neurons
(♂=14, ♀=7)/11 mice (♂=6, ♀=5) (1.5 months), 19 neurons (♂=12, ♀=7)/13 mice (♂=8,
♀=5) (4 months), and 15 neurons (♂=8, ♀=7) /10 mice (♂=5, ♀=5) (10 months) in the
5xFAD dataset.
4.3.4.2 Input/Output
For measures obtained during synaptic activation, cells were held at -70 mV and
stimulated every 10 s. Data reported were derived from 11 neurons (♂=6, ♀=5)/7 mice
(♂=4, ♀=3) (1.5 months), 13 neurons (♂=5, ♀=8)/10 mice (♂=5, ♀=5) (4 months), and 10
neurons (♂=7, ♀=3)/7 mice (♂=5, ♀=2) (10 months) for the WT dataset, and 19 neurons
(♂=13, ♀=6) /11 mice (♂=6, ♀=5) (1.5 months), 16 neurons (♂=10, ♀=6)/12 mice (♂=8,
♀=4) (4 months), and 12 neurons (♂=8, ♀=4)/9 mice (♂=5, ♀=4) (10 months) in the
5xFAD dataset. Excitatory post-synaptic potential (EPSP) amplitudes determined from an
increasing series of activation voltages were plotted to generate I/O curves and used to
determine the threshold for an AP.
4.3.4.3 Repeated Synaptic Stimulation
Stimulation intensity during repeated synaptic stimulation (RSS; 10 s, 7 Hz) was
set at the threshold for an AP. Outcome measures included synaptic hyperpolarization and
potentiation of EPSPs in relation to measures of the first EPSP (baseline) in the train.
Synaptic hyperpolarization was tabulated as the mean peak hyperpolarization amplitudes
following the 6th through 9th EPSPs. The growth of the EPSP during the train was measured
early (EPSPs 6 through 9) and late (last 4 EPSPs).
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4.3.5 Ca2+ Imaging
All cells were imaged after measures of input resistance, AHP, and I/O slopes were
taken. Data reported were taken from 8 neurons (♂=5, ♀=3)/5 mice (♂=3, ♀=2) (1.5
months), 7 neurons (♂=3, ♀=4)/6 mice (♂=3, ♀=3) (4 months), and 7 neurons (♂=5,
♀=2)/5 mice (♂=4, ♀=1) (10 months) for the WT dataset, and 13 neurons (♂=8, ♀=5)/10
mice (♂=6, ♀=4) (1.5 months), 9 neurons (♂=6, ♀=3)/8 mice (♂=5, ♀=3) (4 months), and
8 neurons (♂=5, ♀=3)/6 mice (♂=3, ♀=3) (10 months) were included for the 5xFAD
dataset. Cells were visualized under a 40x objective using a filter cube (Ex: 470/40 nm;
Em: 525/50; Dichroic 495 nm; Chroma Technology Corp.; Bellows Falls, VT). Imaging
Workbench (INDEC BioSystems; Los Altos, CA) was used to quantify outcome measures.
A Lambda DG-4 (Sutter Instruments; Novato, CA) was used as a source to activate the
fluorophore with exposures in the range of 250-800 ms depending on the depth of the cell
imaged. A photometrics camera (Teledyne Photometrics; Tucson, AZ) was used to image
Ca2+ fluorescence and kinetics. Two regions of interest (ROI) were created: one around the
cell body and another of similar size in tissue adjacent to the imaged cell. Background
subtraction and normalization to baseline were used to quantify changes in fluorescence
(% ΔF/F). For quantification of resting fluorescence, values were averaged before RSS and
normalized to the depth of the recorded cell. Outcome measures also included rise time,
peak amplitude, decay time, and area-under-the-curve (AUC) during RSS, and were
derived using Clampfit (Molecular Devices LLC.; San Jose, CA) and SigmaPlot software
(Systat Software, Inc.; San Jose, CA).
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4.3.6 Morris Water Maze
Water maze experiments were performed at the University of Michigan as
previously described [534-536] utilizing male and female 5xFAD mice and non-carrier
littermates (WT) as controls. Three age groups were examined; 1.5 month (5xFAD: ♂=5,
♀=2; WT: ♂=2, ♀=5), 4 month (5xFAD: ♂=4, ♀=4; WT: ♂=4, ♀=3) and 10 month
(5xFAD: ♂=17, ♀=19; WT: ♂=28, ♀=11). A larger cohort of 10-month animals was used
to provide sufficient power to detect differences that we anticipated would be modest
between genotypes at this time point. The MWM was composed of a round white acrylic
pool that was 1.2 m in diameter. The pool was filled with water that was made opaque
using nontoxic, white tempera paint and heated to 28°C. A round platform made of clear
acrylic (10 cm in diameter) was submerged just below the surface of the water, ~ 20 cm
from the edge of the pool in the northeast quadrant. Mice were tracked using a digital
camera mounted above the pool in combination with Actimetrics Water Maze (V4)
software. Mice were trained to find the hidden platform during 4 trials a day. Before each
trial, mice were individually placed on the platform for 10 s. At the start of the trial, mice
were released into the maze, facing the wall at predefined pseudo-random locations, and
the time taken to reach the platform was recorded. For all trials, mice were given 60 s to
find the platform, and, if unsuccessful, were then guided to the platform. Previous
experience indicated that older mice (regardless of genotype) require additional training to
perform above chance. Therefore, young mice (1.5-month and 4-month) received 9 days
of training and the older mice (10-month) received a total of 12 days of training. Mice were
tested for their long-term memory for platform location during several probe tests
throughout training. All mice received probe trials on days 4, 7 and 10 (24 hrs after the last
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training trial). Aged mice (10-month) received an additional probe trial on day 13 (24 hrs
after the last training trial). For the probe trials, the platform was removed from the pool,
and each mouse was allowed to swim for 60 s, starting at a point directly opposite to the
trained platform location. To control for motivation, swimming ability, and sensory
perception (elements required for spatial recognition), mice were run in the visibleplatform version of the water maze on the day following the final probe trial. In this version,
a distinct local cue (a flag) was fixed to the center of the hidden platform. Mice were given
four visible-platform trials with a maximum of 60 s per trial.
4.3.7 Tissue Section for β-amyloid and BTA-1 Staining
Male and female 5xFAD mouse brains were harvested for β-amyloid plaque
staining at 3 time points; 1.5-month (n =15 sections from 3 mice; ♂=5, ♀=10), 4-month
(n = 16 sections from 3 mice; ♂=16, ♀=0) and 10-month (n = 11 sections from 2 mice;
♂=5, ♀=6). Mice were anesthetized using aerosolized isoflurane, then cardiac-perfused
with 1x PBS followed by 4% paraformaldehyde. Brains were removed, further fixed in 4%
paraformaldehyde overnight at 4oC, and then placed in a 30% sucrose solution at 4oC until
they sank (2-3 days). Brains were then embedded in optimal cutting temperature (OCT)
compound (Fisher; Maltham, MA) and frozen at -80°C. Once frozen, the embedded brains
were sliced coronally at 40 μm on a cryostat (Leica; Buffalo Grove, IL) and immediately
mounted on Superfrost Plus slides (Fisher). Once mounted, sections were washed three
times with 1x PBS to remove any residual OCT followed by incubation in 10 μM BTA-1
(Sigma-Aldrich; St. Louis, MO) for 30 min. Sections were then washed for an additional
three times with 1x PBS before being cover-slipped using VectaMount® Aqueous
Mounting Media (Vector Laboratories; Burlingame, CA).
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4.3.8 β-amyloid Imaging
Images were collected from two subregions of the hippocampus: the CA1 and
dentate gyrus (DG) subfields. Images were obtained using an upright laser scanning
confocal microscope (Olympus; Center Valley, PA) equipped with 4x and 20x air
objectives. For each region, single images (1024 x 1024 pixels) were captured every 5 µm
for a total of 15 um total depth. BTA-1 staining was visualized using a 405 nm laser.
Imaging acquisition settings (voltage (HV), gain, and offset) in the Olympus FluoView
software were consistent across samples to allow for comparison. β-amyloid images were
processed using ImageJ software (FIJI) and quantified using maximum projections of
images at a depth of 15 µm. The images were then background subtracted with a 50-pixel
rolling-ball radius, manually thresholded, and converted into binary masks of BTA-1
positive ROIs. ROIs were then used to count individual Aβ plaques in the raw image. This
value was then divided by the volume of the image to give a result of plaque density in
number/μm3. Images are presented in grayscale.
4.3.9 Cell Health and Exclusion Criteria
Only neurons

that

fit

the

following

criteria

were

included

in

the

electrophysiological and Ca2+ imaging analyses: input resistance ≥ 30 MΩ, holding current
≤ -350 pA, and AP peak ≥ -2 mV. These values are reported in Table 4.1. Additionally, if
the number of APs during RSS were > 2 SD from the mean, the cell was considered an
outlier and removed from the analysis.
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4.3.10 Data Quantification and Statistics
The statistical significance of electrophysiological and imaging measures was
calculated using SigmaPlot. Using three-way ANOVA, we report on main effects of age,
sex, or genotype, as well as interaction terms using the Holm-Sidak multiple comparisons
test. For behavioral analysis, significance was tested using a 2-factor repeated measures
ANOVA, unpaired t-tests, and single factor t-tests. Sex differences were not investigated
for behavior. All β-amyloid imaging data was analyzed and displayed using GraphPad
Prism 8 and Aβ deposition between 4-month and 10-month mice was compared using a 2tailed unpaired t-test. The 1.5-month mice were excluded from analysis due to the absence
of any observable plaques. Significance for all data was set at p < 0.05. Data are represented
as means ± standard error of the mean (SEM).
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Table 4.1. Measures of Neuronal Health and Cellular Activation.
Genotype

Age
(months)

Holding
Current (pA)

Input
Resistance
(MΩ)

AP
Amplitude
(mV)

# of APs
During
Imaging

WT Male

1.5

-125 ± 65.1

91.3 ± 15.2

4.5 ± 2.3

70.2 ± 3.0

4

-241.7 ± 16.6

48.7 ± 2.6

7.7 ± 1.5

70 ± 0.6

10

-143.3 ± 31.6

63.3 ± 3.9

8.7 ± 1.8

66.8 ± 4.5

1.5

-76.4 ± 27.5

71.4 ± 4.8

9.2 ± 1.6

68.1 ± 2.2

4

-208.3 ± 22.8

43.3 ± 2.1

8.8 ± 1.3

70 ± 0.7

10

-156.3 ± 36.1

61.0 ± 4.7

7.8 ± 1.9

73.8 ± 1.2

1.5

-120 ± 48.1

76.5 ± 10.7

10 ± 2.1

68.7 ± 0.3

4

-120 ± 27.6

54.6 ± 4.6

9.1 ± 1.8

66.8 ± 4.3

10

-105 ± 33.8

85.1 ± 12.2

8.8 ± 1.9

70.0 ± 0

1.5

-201.4 ± 28.1

61.5 ± 7.7

5.6 ± 2.5

68.2 ± 3.2

4

-185.7 ± 17.6

58.7 ± 6.0

2.9 ± 2.2

70.3 ± 0.3

10

-84.3 ± 40.1

80.0 ± 4.9

6.5 ± 1.6

70.7 ± 0.3

-

p < 0.02

p < 0.001

n.s.

n.s.

5xFAD Male

WT Female

5xFAD Female

Significance
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Table 4.1. Measures of Neuronal Health and Cellular Activation. Neuronal
health was compared across genotype, sex, and age. The amplitude of APs during AHP
data acquisition and the number of APs during RSS while imaging were recorded. Holding
current and input resistance reflect cell membrane “leakiness” and integrity. Holding
current and input resistance at 4 months were both significantly elevated (p < 0.05). No
changes were detected between groups on measures of AP amplitude or number of APs
during imaging (p > 0.05).
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4.4

Results

The following results were derived from 93 cells recorded in 61 animals and from 52
imaged cells. We compared several measures of neuronal health and numbers of APs
triggered during imaging protocols to confirm that the results reported here were all derived
from healthy dorsal CA1 pyramidal neurons (Table 4.1). For behavioral analysis, 55 WT
and 51 5xFAD mice were used. Tissue sections from eight 5xFAD mice were stained and
analyzed for β-amyloid deposits. Table 4.2 illustrates the impact of training as compared
to genotype on MWM outcome measures.
4.4.1 Afterhyperpolarization
To determine if an age, sex, or genotype effect on the Ca2+-dependent AHP was
present, we measured the mAHP and the sAHP amplitude, as well as the AHP duration
(Figure 4.1). These measures revealed that the amplitude of the mAHP (F2,92 = 9.99, p <
0.001; three-way ANOVA; Fig. 4.1B) was significantly reduced in both WT and 5xFAD
mice from 6 weeks to 4 months of age. Interestingly, from 4 to 10 months, the mAHP
significantly increased to levels indistinguishable from those seen at 6 weeks. Similar
results were seen on measures of the sAHP amplitude (F2,92 = 11.00, p < 0.001; three-way
ANOVA) and the AHP duration (F2,92 = 10.70, p < 0.001; three-way ANOVA; Fig. 4.1C).
The “U” shaped aging effect seen in Fig. 4.1 is intriguing, and may reflect on the inclusion
of the 1.5-month age group. In fact, most studies of aging use 3-4 months old animals as
the “young” age group. Still, one prior study using patch electrodes describes a significant
increase between 1.5 months and 1.5 years in similar WT and transgenic animals, but no
significant genotype effect was reported at any ages [127]. Of interest, analysis of the sAHP
amplitude here revealed a significant sex by genotype interaction term (F1,92 = 5.47, p =
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0.02), where a reduction was noted in female 5xFAD compared to WT (p < 0.05), but not
in males. Further, when analyzing the AHP duration (Fig. 4.1D), an age by sex interaction
term was noted (F2,92 = 3.30, p = 0.04); again, this aging effect was only significant in
females (p < 0.05). These results highlight the importance of investigating sex differences
in animal models of AD.
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Table 4.2. Results and Statistical Analyses of Behavioral Data.
Measure
Latency to
Platform

Effect of
Training

Effect of
Genotype

Time spent in
target
quadrant

Effect of
Training

Effect of
Genotype

Swim Speed
Effect of
Genotype

Age (months)

F-value

p-value

Significance

1.5

F(8, 88) = 11.26

P < 0.0001

Yes

4

F(8, 96) = 4.896

P < 0.0001

Yes

10

F(12, 876) = 68.14

P < 0.0001

Yes

1.5

F(1, 11) = 2.395

P = 0.15

No

4

F(1, 12) = 0.008

P = 0.929

No

10

F(1, 73) = 10.53

P = 0.0018

Yes

1.5

F(2, 22) = 12.21

P = 0.0003

Yes

4

F(2, 24) = 0.666

P = 0.523

No

10

F(3, 228) = 24.33

P < 0.0001

Yes

1.5

F(1, 11) = 0.006

P = 0.938

No

4

F(1, 12) = 0.198

P = 0.663

No

10

F(1, 76) = 12.03

P = 0.0009

Yes

1.5

F(5, 6) = 1.179

P = 0.022

Yes

4

F(6, 7) = 4.374

P = 0.404

No

10

F(36, 36) = 2.266

P = 0.8725

No
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Table 4.2. Results and Statistical Analyses of Behavioral Data. Latency to
platform, time spent in the target quadrant, and swim speed were compared across genotype
and age. Training significantly reduced the latency to platform across age (p < 0.0001);
however, on measures of time spent in target quadrant, this was only seen in 1.5- and 10month old animals (p < 0.001). Compared to WT littermates, 5xFAD mice showed
significant behavioral deficits by 10 months of age (p < 0.0018) and spent significantly less
time in the target quadrant (p = 0.0009). Genotype significantly influenced swim speed at
1.5 months (p = 0.022), but not at 4 or 10 months.
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Figure 4.1. AHP Measures in WT and 5xFAD Mice Across Age and Sex.
A. Example of an AHP following post-synaptic depolarization with 4 APs. B. A
main effect of aging (p < 0.05) on the mAHP was observed within each genotype and across
sex. C-D. Similar findings were observed on the sAHP (800 ms) amplitude measures, as
well as on the AHP duration. Hashes (#) represent significance in aging at p < 0.05.
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4.4.2 Synaptic Activation
We quantified neuronal excitability during synaptic activation using measures of
EPSP amplitudes and I/O slopes (Figure 4.2A and B). In alignment with the agedependent changes in the AHP presented in Figure 4.1 where a “U” shaped curve was
noted, analysis of the excitability data (I/O slopes) reveals inverse relationships with age,
as highlighted by greater excitability at 4 months. Indeed, a main effect of age was detected
(F2,80 = 8.02, p < 0.001; three-way ANOVA). Further, an age by sex by genotype
interaction was also identified (F2,80 = 5.13, p < 0.008), albeit only at 1.5 and 4 months of
age (p < 0.05 for both). Once again, this effect was more pronounced in female 5xFAD
mice than in males.
We then obtained measures of RSS at 7 Hz, including synaptic hyperpolarization
(Figure 4.3A, B, and C) as well as short-term EPSP facilitation (Fig. 4.3A, B, D, and E).
While synaptic hyperpolarization has been shown to decrease with age in the F344 rats
model of aging [532], no age or genotype effect was identified in the 5xFAD mice and at
the ages tested here (Fig. 4.3C). However, while investigating changes in EPSP facilitation
during RSS (both early and late, Fig. 4.3D and 3E), we noticed a significant increase in the
late phases of EPSP facilitation as a function of age in the 5xFAD model (F2,76 = 4.11, p =
0.02; three-way ANOVA). This result is surprising, given prior literature reporting on
depressed EPSP facilitation with aging [10, 51, 455, 537].
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Figure 4.2. Extracellular Synaptic Activation.
A. Example of EPSPs recorded below and at threshold of an AP. Inset shows
input/output (I/O) plot fit from EPSP amplitudes with increasing stimulation intensity. B.
Synaptic excitability derived from I/O measures (slopes) reveal a significant main effect of
aging across genotypes and sex. Hashes (#) represent significance in aging at p < 0.05.
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Figure 4.3. Repeated Synaptic Stimulation (RSS).
A. Example of RSS showing EPSP potentiation and synaptic hyperpolarization.
Cells were repeatedly stimulated at 7 Hz for 10 s. B. Upward arrows illustrate growth in
EPSP amplitude during RSS and downward arrows show increased amplitude in the
synaptic hyperpolarization. APs are truncated for illustration in A and B. C. Synaptic
hyperpolarization measured during RSS was not altered across aging or genotypes. D-E.
EPSP facilitation taken during the first (early) and last (late) periods of RSS. A main effect
of age was noted on measures of late EPSP facilitation displaying an increase in the older
group, independent of sex. Hashes (#) represent significance in aging at p < 0.05.
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4.4.3 Ca2+ Imaging
Age-, sex-, and genotype-sensitive changes in Ca2+ kinetics and overall somatic
levels were derived from OGB-1 fluorescence before, during, and after RSS (Figure 4.4).
Cells were synaptically-stimulated at 7 Hz for 10 s and changes in fluorescence were
normalized to resting fluorescence (% ΔF/F) just prior to stimulation. Results show that
neither age, sex, nor genotype altered measures of Ca2+ kinetics based on rise time or decay
time constants (Fig. 4.4D and 4E). However, measures of peak amplitude and AUC (Fig.
4.4C and 4.4F) highlighted a significant main effect of age and sex. Measures of peak
amplitude and AUC revealed a main effect of age highlighted mostly by differences
between the 1.5- and 4-month-old groups (F1,51 = 3.71, p = 0.03; F1,51 = 3.54, p = 0.04,
respectively; three-way ANOVA). The same measures also showed an overall main effect
of sex, as highlighted by reductions in fluorescence intensity during RSS in females
compared to males (peak: F1,51 = 6.52, p = 0.02; AUC: F1,51 = 6.14, p = 0.02).
A main effect of genotype on mean resting fluorescence (F1,49 = 8.62, p < 0.01;
three-way ANOVA) was seen with reductions in Ca2+-dependent fluorescence in the
5xFAD compared to WT in both sexes (Figure 4.5). Because OGB-1 fluorescence values
depend on Ca2+ levels, duration of exposure to the indicator, and the depth of the cell
recorded, we normalized mean resting fluorescence to the depth of each cell. While a
significant main effect of age on measures of recorded depth (F2,49 = 3.80, p = 0.03; threeway ANOVA) was noted, this was mostly mediated by an increase in depth in 4-monthold animals and was independent of genotype, and therefore unlikely to have contributed
to the overall genotype effect (Fig. 4.5).
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Figure 4.4. Changes in OGB-1 Fluorescence During 10 s RSS.
A. Example of an imaged OGB-1 loaded neuron. B. Normalized fluorescence
change across time (% ΔF/F) before, during, and after RSS. C. Peak amplitude measures
show both a significant effect of age and sex. D-E. No significant differences were found
in measures of rise or decay time constants. F. AUC shows significant effects of both age
and sex. Hashes (#) represent significance in aging and asterisks (*) represent sex
differences at p < 0.05.
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Figure 4.5. Resting Fluorescence Before RSS.
Mean resting fluorescence was normalized to the depth of each recorded cell.
Significant genotype effect was detected, highlighting reduced fluorescence in the 5xFAD
animals compared to WT. Ampersands (&) indicate significance for genotype at p < 0.05.
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4.4.4 Behavior
We explored the impact of age on hippocampal-dependent learning and memory
using the MWM task [538]. Analysis of latency to find the hidden platform during training
revealed a significant reduction across training days at 1.5 months (F8, 88 = 11.26, p <
0.0001; two-way repeated measures ANOVA), 4 months (F8, 96 = 4.896, p < 0.0001; twoway repeated measures ANOVA), and 10 months (F12, 876 = 68.14, p < 0.0001; two-way
repeated measures ANOVA). As expected, there were no differences between 5xFAD and
WT mice in latency to platform in either the 1.5-month or 4-month groups (Figure 4.6A1B1). However, there was a significant reduction in latency observed in the 10-month group
(F1, 73 = 10.53, p = 0.0018; two-way repeated measures ANOVA) (Fig. 4.6C1), indicating
that the 5xFAD mice have a deficit in their ability to learn the platform location across
training days.
By the final probe trial, 5xFAD mice and their WT littermates in all groups had
spent a significant percentage of time in the target quadrant compared to chance (p < 0.05,
single factor t-test). As expected, there was no effect of genotype in either the 1.5- or 4month groups across probe trials (p = 0.605, p = 0.938, respectively; two-way repeated
measures ANOVA) (Fig. 4.6A2-B2). However, the 10-month 5xFAD mice spent
significantly less time across probe trials searching in the quadrant where the platform was
previously located in comparison to their WT littermates (F1, 76 = 12.03, p = 0.0009; twoway repeated measures ANOVA) (Fig. 4.6C2), indicating a memory deficit for platform
location. No significant difference in swim speed between 5xFAD and WT mice (p =
0.217; unpaired t-test) was noted, establishing that this deficit was not due to alterations in
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either motor function or motivation. Additionally, a non-spatial version of the water maze
was performed in which the escape platform was clearly marked. The 5xFAD and WT
mice exhibited similar escape latencies (p = 0.7114; unpaired t-test), suggesting that the
memory deficit we observed in the 10-month 5xFAD mice was not due to a nonspecific
performance issue. Similarly, no significant differences were observed in performance
during the visible platform in the 1.5-month and 4-month mice (p = 0.33 and p = 0.054,
respectively). With respect to potential sex differences across groups, we did not observe
a statistically significant effect of sex on any of the behavioral performance variables
analyzed. Finally, we did not observe a correlation between MWM performance, Ca2+
dynamics, and sex. Taken together, these data indicate that learning and memory deficits
are present in 5xFAD mice by 10 months of age.
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Figure 4.6. Morris Water Maze Data.
Mice were trained using 4 trials per day for 9 days (1.5- and 4-month-old animals;
A1-B1.) or 12 days (10-month-old animals; C1.) days on the hidden platform task. Memory
performance was assessed using probe trials on days 4, 7, 10 [^] (all age groups; A2-C2.)
and 13 (10-month; C2.). By the final probe, all groups spent significantly more time (>
25%) in the target quadrant. 1.5- and 4-month mice exhibited a significant decline in the
latency to find the hidden platform across training days, but no differences were seen
between genotypes (A1-B1.). There were no significant differences between genotypes
during probe trials (A2-B2.). 10-month-old 5xFAD and WT mice exhibited a significant
decline in latency to find the hidden platform across training days; however, 5xFAD mice
had a longer latency to reach the platform compared to the WT mice (C1.). During probe
trials, 5xFAD mice spent significantly less time in the target quadrant than WT littermates
(C2.), indicating a memory deficit. Asterisks (*), daggers (†), and double daggers (‡)
represent significant values at p < 0.05.
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4.4.5 β-amyloid Deposition
To measure the deposition of Aβ plaques with age, sections from 5xFAD mice at 3
time points (1.5, 4, and 10 months) were stained with BTA-1 and imaged using confocal
microscopy. The plaques density (# of plaques/μm3) within two hippocampal regions (CA1
and DG) was quantified (Figure 4.7). The results show a significant increase in plaque
density in the 10-month mice compared to the 4-month mice in both the CA1 region (p <
0.0001; unpaired t-test) and DG (p < 0.0001; unpaired t-test). These data show an agedependent progressive increase in β-amyloid plaque deposition in both the CA1 region and
DG.
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Figure 4.7. Amyloid-β (Aβ) Plaque Deposits in the Hippocampus of 5xFAD Mice.
Coronal sections (40 μm) of the dorsal hippocampus (AP, -2.0 bregma) from 1.5,
4, and 10-month-old 5xFAD mice were stained with the amyloid imaging agent BTA-1.
A1-C1) Representative images of the hippocampus of 5xFAD mice demonstrating the
observed age-dependent increase in Aβ plaque accumulation and the regions of interest
(ROI) in CA1 and dentate gyrus (DG) that were used to quantify Aβ plaque density. A2,3 –
C2,3) Representative maximum intensity projection images (20x air; 635 µm x 635 µm x
15 µm, Δz = 5 µm) of Aβ plaque deposits in CA1 and DG from 1.5, 4, and 10-month-old
5xFAD mice. Arrows in panel C3 point to BTA-1 stained Aβ plaques. D and E) Aβ plaque
density (plaque #/μm3) was quantified in the CA1 region and DG from 20x images using
the Analyze Particles plug-in in FIJI. Significant differences in Aβ plaque density were
found between 4-month-old and 10-month-old 5xFAD mice. Analysis of the 1.5-monthold mice were not included because no plaques were observed. Hippocampal layers; CA1:
stratum oriens (SO), stratum pyramidale (SP), stratum radiatum (SR), stratum lacunosummoleculare (SLM) and DG: molecular layer (ML), granule cell layer (GCL) and the hilus
(H). Scale bar: 4x images = 200 μm, 20x images = 50 μm. Asterisks (*) represent
significance determined by a 2-tailed unpaired t-test with p < 0.05. Dorsal (D) → Ventral
(V).
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4.5

Discussion
This study examined the relationship between neuronal Ca2+-mediated variables

and aging in a 5xFAD mice on a C57BL/6 genetic background. We conducted this series
of experiments using electrophysiological and imaging techniques to report on changes in
Ca2+ measures in brain aging. These experiments were conducted to test the hypothesis
that, contrary to what is seen in normal aging, measures of Ca2+-mediated processes are
reduced in the 5xFAD transgenic model of amyloidogenesis. We based this on prior reports
showing that L-VGCC density and the AHP are reduced in two different models of AD
[242, 348]. In the current study, we show that changes in Ca2+-mediated potentials and
levels were identified across early age, sex, and genotype. Briefly, reductions in Ca2+mediated processes appear to be more robust in females compared to males in this animal
model of AD (Fig. 4.4). While surprising, these results underscore a significant lack of
alignment between normal aging processes and those initiated in pathological aging,
suggesting that not only is AD not an accelerated form of aging, but that when considering
Ca2+ dysregulation, these processes may actually diverge. Here, several discrepancies from
the canonical Ca2+ hypothesis of brain aging and dementia were noted, including 1) the
presence of a reduced AHP at 4 months compared to 1.5 and 10 months, 2) the presence of
significant reductions in OGB-1 fluorescence (peak amplitude and AUC) in females
irrespective of genotype, and 3) reduced resting fluorescence in 5xFAD mice compared to
WT.
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4.5.1 Onset of Ca2+ Dysregulation
The amyloidogenic 5xFAD model mimics human AD at an accelerated pace and
presents with amyloid deposition by 1.5 to 2 months, cognitive deficits and synaptic
impairment by 4 months, and neuronal loss by 6 months of age [495]. While this transgenic
design is extremely well-suited for studies of specific phenotypes (e.g. Aβ deposition,
behavior, Ca2+ dysregulation, oxidative stress), the aging component is seldom considered
in the experimental design, likely due to the reduced life-span of these animals. Using
5xFAD mice on a C57BL/6 genetic background, we sought to incorporate components of
aging within the context of AD. Compared to the original report [495], 5xFAD mice on a
C57BL/6 genetic background presents with behavioral deficits starting at 10 months vs. 3
months of age (Fig. 4.6). With respect to the aging effect identified, our results are
surprising, as a significant reduction in the AHP at 4 months of age (Fig. 4.1) was combined
with an increase in excitability (Fig. 4.2) and a lack of change in short-term synaptic
plasticity (Fig. 4.3) or OGB-1 fluorescence (Fig. 4.4). It should be noted, however, that
relatively similar results in response to age were previously reported in the F344 rat model
of aging, where Ca2+ dysregulation (measured through either the AHP or Ca2+ levels) did
not manifest until 12 months of age [135]. One limitation of our study may be that we did
not investigate animals at later time points. Also, very few prior studies have investigated
the Ca2+-dependent AHP at 1.5 months of age ex vivo (i.e. slices), suggesting more analyses
around this age are warranted [127]. The “U” shape curve (a reduction at 4 months)
presented in Fig. 4.1 is reminiscent of prior work in the retina measuring L-VGCC Ca2+
flux in vivo using manganese-enhanced MRI [539-541]. In disease models with
progression of the neurodegenerative events ranging from days to weeks and months

110

(ischemic reperfusion, retinitis pigmentosa, or even diabetes, respectively), Berkowitz and
colleagues find significant prodromal reductions in Ca2+ influx in response to initial
stressors; over time manganese uptake/ L-type Ca2+ channel function appears to return to
seemingly normal levels. Whether our “U” shape curve reflects on a combination of
developmental/maturation processes or aging changes, or on initially competent Ca2+
handling processes that ultimately fail at latter stages requires further investigations.
Based on the increase in the Aβ load (Fig. 4.7) and the time course of progression,
it seems clear that Ca2+ dysregulation does not parallel Aβ increases. Our current results
cannot confirm that amyloid deposits in the dorsal hippocampus alter either neuronal
physiology or Ca2+ kinetics; however, independent of age, a reduction in resting Ca2+
fluorescence was seen in the 5xFAD compared to the WT (Fig. 4.5). Therefore, in this
model, no evidence of enhanced Ca2+ dysregulation was seen using sharp electrode
recording techniques, and instead, possible reductions in Ca2+ processes were noted.
4.5.2 Differences in Techniques
Two prior studies have investigated differences between sharp electrode recording
techniques and whole-cell recordings using patch electrodes [542, 543]. Aside from clear
differences in recording stability and duration (AHPs can be recorded for hours in the same
cell under sharp electrode conditions), input resistance and leak conductance, and the use
of supplemented nucleotides, Ca2+ buffers, and K+ salts, it is clear that under whole-cell
recording conditions, a large amount of APs are needed to elicit a significant AHP [9, 127,
294, 543, 544]. Here, as previously reported in numerous studies of aging, we quantified
the AHP following a series of 4 APs and observed that the Ca2+-dependent potentials were
smaller than those recorded from rat neurons [2, 7]. Typically, the mAHP amplitude in
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young mice is approximately ~1.4 mV [242, 348], while the AHP (recorded with the same
number of APs) from rat neurons is ~2.8 mV [135, 242, 532, 545]. This difference in
technique is important when comparing measures of Ca2+ biomarkers across animal models
of aging and AD and may underlie the current novel results while using sharp electrode
physiology. Nevertheless, this does not necessarily negate previous work using Ca2+
imaging techniques in combination with patch-clamp electrophysiology, where several
underlying mechanisms have been identified in the context of aging and AD [127, 160,
241, 281, 290, 292-294, 297, 299, 512, 546]. In fact, recent studies have presented
compelling evidence that Ca2+-dependent neuronal measures of hyperactivity are present
in the amyloidogenic brain.
4.5.3 Alternative Ca2+-Dependent Biomarkers in AD: Hyperactivity
Several recent studies show that a new Ca2+-dependent biomarker of AD,
previously unseen in in vitro studies, may be neuronal hyperactivity. Using in vivo
multiphoton imaging, these studies have shown that, depending on the proximity to Aβ
plaques, a significant increase in hyperactivity in several neuronal fields in the
amyloidogenic brain is seen [335-337, 339, 340, 547, 548]. Moreover, hyperactivity in
astrocytes adjacent to Aβ plaques has also been reported [549, 550], in some cases with
concomitant increases in spontaneous vasoconstriction [551]. One suggested mechanism
for increased neuronal hyperactivity in AD may be the reduction in glutamate reuptake via
a reduction of glutamate transporters in the microenvironments surrounding Aβ plaques
[340, 547]. Alternatively, this hyperexcitability could develop in response to failing Ca2+
buffering mechanisms, similar to those seen in basal forebrain neurons in aged animals [13,
16, 161]. Together, these alterations highlight the presence of increased hyperactivity in
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neuronal circuits of AD which would likely translate into altered network communication
during encoding.
As one may suspect, this increase in hyperexcitability could reflect on the presence
of an epileptic-like phenotype in some models of AD [258, 552-556]. Age-dependent
susceptibility to epilepsy has been well documented in the literature, with marked increases
of epilepsy development reported in the elderly [557-561]. Epilepsy has long been
characterized as a disease of neuronal hyperexcitability and abnormal firing with
dysregulated Ca2+ as a key contributor [259, 562-567]. It is becoming evident that there is
clear overlap between the profiles of these two diseases. A recent study performed in a rat
model of epileptogenesis used bioinformatics to identify regulatory proteins in the
hippocampal and parahippocampal brain regions that overlap in AD and epilepsy [513].
Among the shared dysregulated proteins of these diseases, 63 were identified to be
involved with both mitochondrial function and Ca2+ homeostasis. At the least, these
alterations certainly highlight AD as a disease of synaptic dysfunction that propagates
intracellular dysregulation. Thus, it is clear that further characterization of this novel Ca2+dependent biomarker of AD is needed.
While previous work in the field of neuronal excitability in aging has mostly
remarked on reduced synaptic excitability, especially with respect to the larger AHP, but
also reduced synaptic connectivity [2, 8, 9, 294, 568-571], our results showing an agedependent reduction in the AHP (at 4 months), elevations in I/O slope, and reductions in
resting Ca2+ align relatively well with a potential phenotype of hyperexcitability. As
expected, reductions in Ca2+ and Ca2+-mediated cellular events (i.e. AHP) seem likely to
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engage hyperactivity processes, increase network communication, and, perhaps, reduce the
threshold for epileptogenesis in this animal model of AD.

4.6

Conclusions

While our study does not identify increases in Ca2+ dysregulation in the 5xFAD animals
compared to WT littermates across age, it does highlight the possibility that Ca2+-related
processes in aging may be significantly different than those seen in AD. Further, studies
investigating older animals (i.e. > 12 months of age) are needed to test whether Aβ
accumulation induces Ca2+ dysregulation. It appears that neuronal hyperactivity may be a
reliable reporter of Ca2+ dysregulation in AD; as such, further in vivo investigations are
needed to identify new therapeutic strategies targeting anti-epileptic processes. In fact, both
basic research studies and clinical trials have already been initiated to explore the efficacy
of anti-epileptic drugs in the context of AD, with potentially promising results having been
reported [260, 572-577]. Additional investigations will be needed as we further elucidate
the precipitating factors involved with these two disease states.
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CHAPTER 5. DISCUSSION, LIMITATIONS, AND FUTURE DIRECTIONS
5.1

Discussion
5.1.1 Recap of Aldh2-/- and 5xFAD Study Results
Using sharp electrode electrophysiological and Ca2+ imaging techniques, direct and

indirect Ca2+-dependent processes were characterized in two AD mouse models at 1.5, 4,
and 10 months of age. These models, the Aldh2-/- and 5xFAD, were specifically chosen to
represent sporadic and familial Alzheimer’s disease, respectively. Further, these models
manifest similar AD phenotypes progressively, from birth, that align relatively well with
the early phases of aging. The Aldh2-/- model develops high quantities of lipid peroxidation
byproduct HNE through the knockdown of the ALDH2 gene, which promotes elevated
oxidative stress, morphological and quantitative atrophy to dendritic processes, Aβ
monomers and oligomers, phosphorylated tau, and cognitive impairment. The 5xFAD
mouse, however, develops amyloid deposits, synaptic dysfunction, and cognitive deficit
phenotypes through the genetic manipulation of APP, PSN1, and PSN2 genes. As neuronal
Ca2+ handling has not been well characterized alongside aging in animal models of AD, it
was of interest to directly measure Ca2+, as well as Ca2+ signaling in these two very different
mice.
The significant findings of these two studies illustrate that Ca2+-mediated
alterations differ across animal models of AD. In the Aldh2-/- study, very few neuronal
alterations were observed despite the increasing levels of oxidative stress as the mice aged.
Of these alterations, only an age-related decrease in the AHP, a genotype-mediated
elevation in the slow AHP amplitude, and a genotype-driven decrease in LTP maintenance
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were noted in the Aldh2-/- knockout group. Alternatively, in addition to MWM behavioral
deficits and increases in amyloid deposits with age, 5xFAD mice showed considerable
changes in their neuronal physiology. Indeed, while age-related decrease (1.5 to 4 months
of age) and increase (4 to 10 months) in amplitude were noted across 5xFAD and WT
genotypes in AHP measures, a robust sex difference was present during Ca2+ imaging
showing less Ca2+ in neurons of female mice during synaptic stimulation. Further, in
general, 5xFAD mice had less resting Ca2+ compared to their WT counterparts, irrespective
to age or sex. Together, these studies showed no evidence of increased neuronal Ca2+ to
propagate the development of AD-like phenotypes in either model.
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Table 5.1. Summary of Aldh2-/- and 5xFAD Results.

Outcome Measure

5xFAD Male

5xFAD
Female

Aldh2-/Male

sig. age “U”

sig. age “U”

sig. age ↓

Aldh2-/Female
sig. age ↓

mAHP (mV)

sig. sex ↓
AHP
sAHP (mV)

I/O Slope
(mV/V)

sig. age “U”

sig. age ↓

sig. age ↓

sig. gen. ↓

sig. gen. ↓

sig. age “U”

Duration (s)

sig. age “U”

sig. age “U”

n.s.

n.s.

Synaptic
Activation

sig. age “U”

sig. age “U”

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

sig. age ↑

sig. age ↑

n.s.

n.s.

n.s.

n.s.

n.s.

n.s.

Synaptic
Hyperpolarization
(mV)
RSS

Early EPSP
(% FF)
Late EPSP
(% FF)
AUC

sig. age ↑
sig. age ↑

(ΔF/F (%)*s)
Ca2+ Imaging

Peak Amplitude

(During RSS)

(ΔF/F (%))

sig. sex ↓
sig. age ↑
sig. age ↑
sig. sex ↓

Rise Time (s)

n.s.

n.s.

n.s.

n.s.

Decay Time (s)

n.s.

n.s.

n.s.

n.s.

sig. gen. ↓

sig. gen. ↓

n.s.

n.s.

Normalized Resting Fluorescence
(F/um)
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Table 5.1. Summary of Aldh2-/- and 5xFAD Results. Compilation of neuronal
Ca2+ handling results across age, genotype, and sex in Aldh2-/- and 5xFAD mouse models.
An age-mediated reduction in the AHP amplitude was observed in the mAHP and sAHP
outcome measures of the Aldh2-/- mice. Additionally, a main effect of sex was present as a
reduction in the mAHP, while a genotype-driven decrease in the sAHP was also identified
in the Aldh2-/- group. In the 5xFAD mice, measures of the mAHP, sAHP, and AHP duration
showed a decrease from 1.5 to 4 months of age, followed by an increase from 4 to 10
months. This unique “U” shaped curve is discussed in Chapter 4.5.1. Measures of synaptic
activation via an I/O curve revealed an increase, then a decrease across age in the 5xFAD
mice; an expected inverse of the AHP data. While no other significant alterations were
identified in outcome measures of the Aldh2-/- data, significant age-related increases were
observed in late EPSP, AUC, and peak amplitude measures of the 5xFAD mice. Further, a
sex-mediated reduction in the AUC and peak amplitude was noted in female 5xFAD
animals. A main effect of genotype was also seen in the 5xFAD group as a reduction in
resting fluorescence. Significance was determined as p < 0.05. A main effect of age is
highlighted in yellow, sex in blue, and genotype (gen.) in green. No significance is
represented as “n.s.”.
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5.1.2 Familial vs. Sporadic AD Model Design
With inconsistencies of Ca2+ dysregulation (i.e. elevations and reductions)
observed in both animal and culture models of AD (here and in previous literature), perhaps
the initial hypothesis that elevated neuronal Ca2+ in AD progression is a gross
generalization that lacks relevance across all AD models. Considering fAD only accounts
for a small fraction (~5%) of total human AD cases and sAD (95%) remains more
prevalent, the primary use of transgenic models with fAD gene mutations in AD research
may be hindering the growth of the field. Further, it is important to note that in addition to
fAD cases being less prevalent, symptoms manifest as early as 30 years of age and this
type of dementia is not only more severe, but progresses faster. With sAD patients
generally showing symptoms by 65 years of age and progressing more slowly, research
models have not been effectively recapitulating AD phenotypes to mimic what is observed
in humans. However, it should be emphasized that the focus on using fAD models in AD
research is due to the poorly understood nature of sAD development, as the latter is likely
due to a culmination of genetic, environmental, lifestyle, and metabolic risk factors. That
being said, the understanding of sAD is still developing. Only recently was an ER and
plasma membrane channel called calcium homeostasis modulation 1 (CALHM1) identified
as being linked to a gene polymorphism that increases sAD risk by decreasing Ca2+
permeability and increases Aβ production [578, 579]. Nevertheless, as fAD and sAD have
similar phenotypes, there is value in drawing comparisons between research models of
each type to better understand AD development and progression as a whole. In addition to
the incorporation of genetic mutations, careful consideration of an animal’s genetic
background should be made when selecting a research model to study.
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5.1.3 Genetic Background of Research Models
Importantly, an animal’s genetic background can drastically alter phenotypic
expression, meaning greater emphasis must be placed on comparing animal models of like
backgrounds. Indeed, early studies assessing the impact of genetic backgrounds on learning
behavioral tasks and fear conditioning have squarely implicated animal strain as a
participating factor in both learning enhancements and deficits [580]. In concert with gene
mutations, genetic background differences can elicit staggering variability to physiological
phenomena like neuronal excitability and the post-burst AHP as well [431]. Additionally,
choosing whether to work with an inbred or outbred strain of an animal model is just as
important. While an enhancement in the AHP has classically been shown in aged inbred
F344 rats [182], the outbred Long Evans rat model seems to show a reduction in the AHP
of aged animals [581]. Here, the Aldh2-/- and 5xFAD mouse strains were both of a C57BL/6
genetic background in the experimental studies. Thus, genetic background variability
should not have confounded data comparisons between the respective mouse models.
5.1.4 Neuronal Excitability in the Animals
In Chapter 4.5.3 it was discussed how in the 5xFAD mice there was an observed
increase in neuronal excitability accompanied by a reduction in the AHP, decreased levels
of resting Ca2+, and the early production of Aβ plaques by 4 months of age. As AD and
epilepsy profiles seem to share many dysregulated proteins [513] and considering the
growing evidence of neuronal hyperactivity in the amyloidogenic brain [335-337, 339, 340,
547, 548], we concluded that, perhaps, a reduced threshold of epileptogenesis could be the
byproduct of dysregulated Ca2+ and Ca2+-mediated processes. It is curious, however, that
while Aβ promotes oxidative stress [229], synaptic deficits [230], and excitotoxicity [229,
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231], we should see very little change in hyperactivity in the Aldh2-/- mice. Given the wellestablished relationship between ROS promoting neuronal hyperexcitability [582-585], it
is surprising that no increases in excitability were noted in the Aldh2-/- mice, a model of
excess oxidative stress. Notably in contrast to the 5xFAD, we saw no changes in resting or
stimulated Ca2+ levels in neurons of the Aldh2-/- mice. Also, while Aβ has been
characterized in the Aldh2-/- mice, no histochemical staining of plaques was conducted in
this study, therefore the severity of plaque deposition in the Aldh2-/- mice may be
significantly less than in the 5xFAD. It is possible that oxidative stress alone is not enough
to promote the hyperexcitability phenotype, but rather it is when oxidative stress is coupled
with pronounced dysregulated Ca2+ or Aβ plaques that chronic excitability persists.
5.1.5 Animal Sexes
With a by and large push for sex inclusion as a variable in basic research, we
decided to acquire data from both male and female mice in each study. To our surprise, sex
differences were mostly absent across outcome measures. In the 5xFAD data, significant
reductions in the area-under-the-curve and peak amplitude Ca2+ measures were observed
in neurons from female mice compared to their male counterparts, regardless of genotype.
Though sex differences were not shown in the Aldh2-/- study (due to low n) as stated in
Chapter 2.4.2, a significant sex-mediated reduction in the mAHP of female mice was
indeed present. Upon combining sexes, an age-driven decrease in the mAHP was present
in both Aldh2-/- and WT mice. As past work has shown, estrogen plays an important role
in the mediation of Ca2+-dependent processes. As estrogen levels decrease, L-VGCC
expression increases [122], while application of estrogen receptor agonists decrease the
AHP amplitude [102], elevate NMDA receptor density [71], increase dendritic spines and
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synaptic density [187, 509], mitigate age-mediated L-VGCC current increases [96], and
reduce intracellular Ca2+ release [191]. Thus, our results of reduced Ca2+ during synaptic
stimulation in neurons of female mice compared to males may align with previous
literature. Considering the previously described benefits of estrogen replacement therapy
to reduce AD incidence [96, 353-357], there is clearly a necessity for further measures
pertaining to estrogen in future studies. Moreover, as AD prevalence is three times greater
in women than men likely due to post-menopausal depletions in estrogen levels [185] and
considering rodent perimenopause typically occurs between 9-12 months of age [586-589],
it is also possible that our mice were not aged enough to observe estrogen-mediated
declines in Ca2+ processes. It should be noted, however, that data pertaining to the
reproductive cycle of 5xFAD and Aldh2-/- mice is limited.

5.2

Study Limitations
5.2.1 Animal Age
As measuring changes in neuronal Ca2+ handling during aging was an important

aspect of these studies, it should be noted that, perhaps, our animals were not aged enough
to detect more drastic alterations to the AHP, synaptic plasticity, and Ca 2+ levels. The
selected timelines were indeed favorable to account for recording outcome measures
before, during, and after amyloidogenesis, however, it is possible that the extent of
degeneration was not fully realized by 10 months of age. For instance, in previous work
measuring the AHP in 3xTg and PS1KI mice at 6 weeks, 6 months, and 18 months of age,
a significant age-driven increase was not identified until 18 months [127]. Similarly, in
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3xTg mice of 1, 6-9, and 12-16 months of age, age-dependent increases in NMDA and LVGCC current were only present by 12-16 months [241]. Even regarding measurements of
Ca2+ binding proteins, previous work has shown an increase in calbindin immunoreactivity
of APPSWE/PS1dE9 at 3 months but a decrease by 12 months, suggesting an initial
compensatory mechanism that is later downregulated [309]. Considering our 5xFAD
design was curated to induce a slower developing amyloidogenesis, it is possible that dire
alterations to Ca2+ kinetics are not present until a timepoint beyond 10 months of age. In
the interest of time and limited resources, the truncated timeline (i.e. 1.5, 4, and 10 months)
that was used in our studies did serve the purpose of reporting gradual changes in Ca2+
processes. Nevertheless, it is of interest to acquire data at later ages in future studies to
further characterize a comprehensive picture of neuronal Ca2+ handling during aging.
5.2.2 Shipping of Animals
The inter-lab collaborations of these studies cultivated meaningful exchanges of
knowledge, expertise, and resources. Further, a large component of these collaborations
was the transportation of cohorts of mice from either Queens U. or the U. of Michigan to
the U. of Kentucky. In carefully coordinated shipments, 20+ mice were sent to us at a time,
pending inclement weather conditions were not in the immediate forecast. At times of
extreme weather, transportation of animals was challenging to navigate and impactful to
data acquisition. Considering animals were to be utilized at specific timepoints, during
offset schedules I would have to rearrange my schedule accordingly to accommodate for
these unexpected delays to assure timelines were met. More recently we had plans to
measure network Ca2+ handling using a two-photon imaging approach. However, due to
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the SARS-CoV-2 pandemic of 2020 affecting colony maintenance and shipment of
animals, we had to forego these plans until a later time.
5.2.3 Alternative Brain Regions
While the experiments in Chapters 2 and 4 were conducted using hippocampal
sections, it is of interest to explore neuronal Ca2+ handling in alternative brain structures as
well. As highlighted in Chapter 1, Ca2+ levels, kinetics, and processing seem to vary based
on brain region, which may be linked to a divergence in normal brain aging and a
pathogenic AD brain. In fact, early literature has illustrated significant alterations in Ca2+
metabolism across brain structures as rodents age [590]. For example, while it has been
shown that L-VGCC density, Ca2+ currents, mRNA protein expression levels, and their
post-translational phosphorylation state are increased in hippocampal neurons of aged rats
[80, 95-102], expression patterns and function of L-VGCCs are not altered in cortical
neurons [120, 121]. Further, some CBP activity has been notably decreased in hippocampal
tissue [149-151], but is increased in basal forebrain neurons [16, 160, 161]. These examples
are not exclusive to just animal models, however. As mentioned in Chapter 1, in autopsied
human AD patients reductions of ER IP3R density have been noted in hippocampal and
parietal lobe tissue, but no significant alterations were present in frontal, temporal, or
occipital lobes [301]. Thus, while this limitation underscores the many permutations of
conducting neuronal Ca2+ handling research as it pertains to a brain structure of interest, it
also highlights the vast amount of possibilities for future directions, especially with regard
to neuronal network communication.
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5.3

Future Directions
5.3.1 Imaging of Ca2+ Network
Indeed, there are many different future directions that this work can take. First and

foremost, our lab has plans to shift the focus of recording Ca2+ changes in single neurons
to two-photon imaging of neuronal and astrocytic networks. Through both adenoassociated virus injections and genetically modified rodents with Ca2+ indicator encoded
neurons, we have already generated promising preliminary data. In 5xFAD mice
genetically modified with GCaMP6, it seems that Ca2+ dysregulation may impact neuronal
density, firing patterns, and distance of communication. It is of interest to assess how
gradual amyloidogenesis (5xFAD) or free oxygen radicals (Aldh2-/-) affect these important
neuronal communication properties. A common concern in single-neuron recordings is that
only healthy neurons are being measured while degeneration-impacted neurons are not
healthy enough to be electrophysiologically recorded. While this is accounted for by
acquiring neuronal health measures (see Chapters 2.4.1 and 4.3.9), field imaging of a
network of neurons that are simultaneously stimulated provide greater insight to the
widespread physiologic implications of neurodegeneration. While single-cell recordings
show a piece of a puzzle, field imaging tells a comprehensive story of how those pieces fit
together and should be considered for future studies.
5.3.2 Amyloid Plaques in Aldh2-/- Mice
Considering that amyloid plaques are widely considered a hallmark of AD and
though concentrations of Aβ have been identified in the Aldh2-/- model, the extent of Aβ
accumulation and how it compares with the 5xFAD mice across age requires more
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attention. In the 5xFAD model, it was clear that by 4 months of age the amyloid deposits
were starting to accumulate in region CA1 and the DG, and were substantially elevated in
both of these hippocampal subregions by 10 months (Chapter 4.4.5). This measurement
elicited valuable comparisons between amyloid load, Ca2+ levels, and pre-/post-synaptic
events including the observation of a reduced AHP and elevated I/O excitability in concert
with amyloid generation. As oxidative stress has been long thought to play a robust role in
APP metabolism [401, 591-595], it is of utmost interest to characterize a timeline of
amyloid plaque progression as it aligns with increasing oxygen radical load. Further,
normalization of Aβ concentrations and neuronal Ca2+ levels between the 5xFAD and
Aldh2-/- models may provide evidence of the magnitude of impact that oxidative stress has
on global cell health. Lastly, with the characterization of Aβ concentrations across age, this
future direction may also lead to identifying how changes in Aβ, Ca2+, synaptic
communication, and oxidative stress affect intracellular regulatory factors like Ca2+
binding protein levels.
5.3.3 Ca2+ Binding Protein Measures
Another important measure that can be further investigated is the impact of the age,
sex, and genotype of these models on the regulation of Ca2+ binding proteins (CBPs). As
discussed in Chapters 1.4.3 and 1.12.3, CBPs have an invaluable role in Ca2+ ion buffering
and signaling that can be compromised during aging and in AD progression. Unfortunately,
measures of CBPs were not conducted in these studies. It would be fascinating to quantitate
various CBPs such as calbindin or calretinin that have been shown to decrease in the
hippocampus of aged and AD animals, which has led to reduced synaptic strength [149,
150, 309, 310]. Further, in the 5xFAD mouse that showed reduced resting Ca2+ compared
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to WT, as well as a sex-mediated decrease in stimulated Ca2+ in females compared to males,
CBP quantification may reveal additional sex- or genotype-related alterations to neuron
physiology in these mice. Also, considering calcineurin has been shown to participate in
the enhancement of L-VGCC function in aging [101, 159], measuring its level of activation
in the context of decreased resting or stimulated Ca2+ may be another outcome measure
worthy of attention. In conjunction with this, the application of Ca2+ agonists or blockers
would surely help to elucidate if L-VGCCs participate in the decreases of Ca2+ observed
in the 5xFAD model.
5.3.4 Ca2+ Blockers and Other Therapeutics
The use of Ca2+ channel agonists and blockers has provided the field with a better
understanding of intra- and extracellular neuronal Ca2+ handling through the
characterization of Ca2+ sources and their function. Additionally, although controversial,
the translatability of Ca2+ channel blockers in clinical studies has helped to validate the
Calcium Hypothesis of Brain Aging and ultimately Ca2+’s role in AD progression. Thus,
as a future direction of these studies, the inclusion of Ca2+-related drugs and other
therapeutics might navigate researchers to better identify the chronological order of
abnormal cellular process as animal models of AD age. For instance, though reduced
resting Ca2+ in the 5xFAD mice and overall less stimulated Ca2+ in females was observed
in that study, it is unclear where the source of decreased Ca2+ originates. If the sex-mediated
reduction in Ca2+ is related to estrogen levels, then perhaps introducing 17beta-estradiol
benzoate to hippocampal slices during electrophysiological recordings might abolish the
AHP amplitude [102]. However, if a reduction in L-VGCC current is present as previously
observed in the 5xFAD mouse [348], as well as the 2xTg model [242], then perhaps
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application of 17beta-estradiol may further reduce L-VGCC activity [96]. If indeed
decreased L-VGCC channel activity is a source of reduced resting Ca2+ in this model, then
it may be of interest to test the effect of L-VGCC agonist Bay K8644 on increasing resting
Ca2+ in the 5xFAD mice [11]. Regarding the Aldh2-/- study, though few phenotypic
alterations were observed, the use of antioxidant or photobiomodulation interventions to
buffer oxidative stress and regulate downstream alterations like Aβ production and
synaptic deficits could be of interest. Overall, great insights can be made by targeting
specific organelles involved in Ca2+ events with therapeutics and determining their impact
in these two models, with respect to age, sex, and genotype.

5.4

Conclusions
Ca2+ is an essential ion involved in many physiologic events necessary for

biological homeostasis. In the brain, Ca2+ is utilized by neurons when eliciting action
potentials in specific patterns and frequencies to communicate neurochemical messages,
as well as in the encoding and erasure of memories. It is important that Ca2+ is regulated at
specific concentrations both inside and outside of neurons to maintain normal action
potential properties. In aging and AD, it has been noted that neuron Ca2+ levels deviate
from homeostatic concentrations, which leads to widespread physiologic impairment. This
deviation, coined “calcium dysregulation”, was once widely thought to manifest as
elevated intracellular Ca2+ levels, as it was historically observed in models of aging.
However, in addition to the work shown here, a growing body of literature suggests that
intracellular neuronal Ca2+ concentrations and handling in AD not only deviates from
normal aging, but may actually be reduced [242, 348, 525].
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Given AD is a neurodegenerative disease that progresses in late-life, it was often
assumed that 1) AD is an accelerated form of aging and 2) elevated intracellular Ca2+ may
give rise to disease development. AD development, however, can be subdivided into two
categories: fAD, which makes up 5% of total cases, and sAD, the other 95%. Basic research
has implicated mutations of the APP, PSN1, and PSN2 genes as primary promoters of fAD,
which have been modeled in transgenic animals of AD. Many fAD models have shown
increased intracellular Ca2+ due to the inclusion of the ER Ca2+ channel-modifying PS
mutations, despite the lack of this genetic mutation in most human AD cases. In fact, many
animal models of AD have shown either no changes or reduced neuronal Ca2+. We sought
to further investigate this by measuring Ca2+ and Ca2+-mediated processes across age in
both fAD and sAD mouse models.
Here, we showed that resting Ca2+ levels were reduced in neurons of a model of
fAD and unaltered in sAD. There were clear AD-related deficits that developed in each
model as the mice aged, but these impairments were not due to elevated neuronal Ca2+. As
Ca2+ dysregulation has been shown to have a robust role in disrupting many neuronal
processes, it is not to say that Ca2+ dyshomeostasis does not warrant downstream cellular
abnormalities. However, perhaps the dogma of the Calcium Hypothesis of Brain Aging has
become too generally accepted and its philosophy of increased neuronal Ca2+ with aging
has somewhat hindered growth of the field. Common factors like genetic background, sex,
and gene mutations clearly impact phenotypic expression of animal models. Coupled with
the fact that the AD field lacks a perfect AD surrogate that mimics human pathology
progression, it is understandable that controversial findings have riddled researchers.
Indeed, it is difficult to control every experimental variable in a study, however through
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the careful consideration of intrinsic biological factors and the influence they may have on
other variables, new doors of discovery will undoubtedly continue to open.
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APPENDIX
List of Abbreviations
Aβ

amyloid-β

ACSF

artificial cerebral spinal fluid

AD

Alzheimer’s disease

AHP

afterhyperpolarization

Aldh2-/-

aldehyde dehydrogenase 2 knockout

AMPA

α-amino-3-hydroxy-5-methylisoxazole-4- propionate

AP

action potential

APP

amyloid precursor protein

ATP

adenosine triphosphate

AUC

area-under-the-curve

CA1

Cornu Ammonis-1

CBP

Calcium binding proteins

CCE

capacitive Ca2+ entry

CICR

calcium-induced calcium release

DG

dentate gyrus

EPSP

excitatory post-synaptic potential
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ER

endoplasmic reticulum

fPSP

field post-synaptic potentials

GCL

granule cell layer

HFS

high frequency stimulation

H

hilus

HNE

4-hydroxynonenal

ICS

intracellular calcium stores

I/O

input/output

IP3

inositol (1, 4, 5)-trisphosphate

KO

knockout

LGCC

ligand-gated calcium channel

LPx

lipid peroxidation

LTD

long-term depression

LTP

long-term potentiation

L-VGCC

L-type voltage-gated calcium channel

mAHP

medium afterhyperpolarization

MCU

mitochondrial Ca2+ uniporter

mNCX

mitochondrial Na+/ Ca2+ exchangers

132

ML

molecular layer

MWM

Morris water maze

NCX

Na+/ Ca2+ exchangers

NMDA

N-methyl-D-asparate

OGB-1

Oregon Green Bapta-1

PMCA

plasma membrane Ca2+ ATPase

PS

presenilin

p-tau

phosphorylated tau protein

ROI

region of interest

ROS

reactive oxygen species

RSS

repeated synaptic stimulation

RyR

ryanodine receptor

sAHP

slow afterhyperpolarization

SC

Schaffer collaterals

SEM

standard error of the mean

SERCA

sarco-endoplasmic reticulum Ca2+-ATPase

SO

stratum oriens

SOCE

store-operated Ca2+ entry
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SLM

stratum lacunosum-moleculare

SP

stratum pyramidale

SR

stratum radiatum

TBI

traumatic brain injury

VGCC

voltage-gated Ca2+ channels

WT

wild-type
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